Page last updated: 2024-12-06

alfentanil

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Alfentanil is a potent synthetic opioid analgesic. It is a phenylpiperidine derivative that was first synthesized in the 1970s. Alfentanil is a short-acting drug with a rapid onset and a short duration of action. It is used in clinical practice for anesthesia, analgesia, and sedation. Alfentanil is metabolized in the liver and excreted in the urine. The compound is commonly studied to investigate its potential uses in various medical settings. Its rapid onset and short duration of action, along with its potent analgesic properties, make it a valuable tool in pain management and anesthesia. Alfentanil is also studied for its potential use in palliative care and in the management of chronic pain.'

Alfentanil: A short-acting opioid anesthetic and analgesic derivative of FENTANYL. It produces an early peak analgesic effect and fast recovery of consciousness. Alfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

alfentanil : A member of the class of piperidines that is piperidine having a 2-(4-ethyl-5-oxo-4,5-dihydro-1H-tetrazol-1-yl)ethyl group at the 1-position as well as N-phenylpropanamido- and methoxymethyl groups at the 4-position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID51263
CHEMBL ID634
CHEBI ID2569
SCHEMBL ID26256
MeSH IDM0024147

Synonyms (66)

Synonym
r-39209
alfenta
rapifen
n-{1-[2-(4-ethyl-5-oxo-4,5-dihydro-1h-tetrazol-1-yl)ethyl]-4-[(methyloxy)methyl]piperidin-4-yl}-n-phenylpropanamide
D07122
alfentanil (inn)
rapifen (tn)
n-(1-(2-(4-ethyl-4,5-dihydro-5-oxotetrazolyl)ethyl)-4-(methoxymethyl)-4-piperidyl)-n-phenylpropionamid
alfentanil [inn:ban]
n-(1-(2-(4-ethyl-4,5-dihydro-5-oxotetrazolyl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilid
brn 1188293
alfentanilum [inn-latin]
dea no. 9737
hsdb 6789
propanamide, n-(1-(2-(4-ethyl-4,5-dihydro-5-oxo-1h-tetrazol-1-yl)ethyl)-4-(methoxymethyl)-4-piperidinyl)-n-phenyl-
71195-58-9
C08005
alfentanil
alfentanyl
n-(1-(2-(4-ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide
DB00802
MLS002320667 ,
smr001338813
CHEMBL634
r-39209-
afentanyl
ids-na-014
L001231
alfentanilum
CHEBI:2569 ,
n-{1-[2-(4-ethyl-5-oxo-4,5-dihydro-1h-tetrazol-1-yl)ethyl]-4-(methoxymethyl)piperidin-4-yl}-n-phenylpropanamide
n-[1-[2-(4-ethyl-5-oxotetrazol-1-yl)ethyl]-4-(methoxymethyl)piperidin-4-yl]-n-phenylpropanamide
n-[1-[2-(4-ethyl-5-oxo-2-tetrazolin-1-yl)ethyl]-4-(methoxymethyl)-4-piperidyl]propionanilide
NCGC00247354-01
NCGC00247354-02
unii-1n74hm2bs7
5-26-13-00110 (beilstein handbook reference)
1n74hm2bs7 ,
EPITOPE ID:153516
n-{1-[2-(4-ethyl-5-oxo-4,5-dihydro-1h-1,2,3,4-tetrazol-1-yl)ethyl]-4-(methoxymethyl)piperidin-4-yl}-n-phenylpropanamide
gtpl7108
alfentanil [mi]
alfentanil [hsdb]
alfentanil [who-dd]
alfentanil [vandf]
n-(1-(2-(4-ethyl-4,5-dihydro-5-oxo-1h-tetrazol-1-yl)ethyl)-4-(methoxymethyl) -4-piperidinyl)-n-phenylpropanamide
alfentanil [inn]
SCHEMBL26256
n-[1-(2-(4-ethyl-5-oxo-4,5-dihydro-1h-tetrazol-1-yl)ethyl)-4-(methoxymethyl)piperidin-4-yl]-n-phenylpropionamide
n-[1-[2-(4-ethyl-5-keto-tetrazol-1-yl)ethyl]-4-(methoxymethyl)-4-piperidyl]-n-phenyl-propionamide;hydrochloride
bdbm83450
n-[1-[2-(4-ethyl-5-oxidanylidene-1,2,3,4-tetrazol-1-yl)ethyl]-4-(methoxymethyl)piperidin-4-yl]-n-phenyl-propanamide;hydrochloride
n-[1-[2-(4-ethyl-5-oxotetrazol-1-yl)ethyl]-4-(methoxymethyl)piperidin-4-yl]-n-phenylpropanamide;hydrochloride
cid_64761
n-[1-[2-(4-ethyl-5-oxo-1-tetrazolyl)ethyl]-4-(methoxymethyl)-4-piperidinyl]-n-phenylpropanamide;hydrochloride
n-[1-[2-(4-ethyl-5-oxo-4,5-dihydro-1h-tetraazol-1-yl)ethyl]-4-(methoxymethyl)-4-piperidinyl]-n-phenylpropanamide #
DTXSID9022570 ,
Q176533
SB17329
alfentanilum (latin)
alfentanilo
n-(1-(2-(4-ethyl-4,5-dihydro-5-oxo-1h-tetrazol-1-yl)ethyl)-4-(methoxymethyl)-4-piperidinyl)-n-phenylpropanamide
n01ah02
dtxcid302570
n-(1-(2-(4-ethyl-5-oxo-4,5-dihydro-1h-tetrazol-1-yl)ethyl)-4-(methoxymethyl)piperidin-4-yl)-n-phenylpropanamide
alfentanilum (inn-latin)

Research Excerpts

Overview

Alfentanil (ALF) is a validated probe for hepatic, first-pass, and intestinal cytochrome P450 (CYP) 3A activity, using plasma clearances, single-point concentrations, and noninvasive pupil diameter change (miosis) It is a low-extraction drug with a clearance that is highly susceptible to drug interactions.

ExcerptReferenceRelevance
"Alfentanil is a derivative of fentanyl, with quicker onset than that of fentanyl and with shorter duration and more intense vagomimetic properties than those of fentanyl and sufentanil."( [New opioids for general anaesthesia and in- and out-hospital analgesia].
Dabrowska-Wójciak, I; Piotrowski, A,
)
0.85
"Alfentanil (ALF) is a validated probe for hepatic, first-pass, and intestinal cytochrome P450 (CYP) 3A activity, using plasma clearances, single-point concentrations, and noninvasive pupil diameter change (miosis). "( Concurrent assessment of hepatic and intestinal cytochrome P450 3A activities using deuterated alfentanil.
Blood, J; Buck, N; Kharasch, ED; Kim, T; London, A; Mach, RH; Vangveravong, S, 2011
)
2.03
"Alfentanil is a low-extraction drug with a clearance that is highly susceptible to drug interactions; fentanyl is a high-extraction drug and, thus, is theoretically less vulnerable."( Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil.
Feldman, J; Ibrahim, AE; Karim, A; Kharasch, ED, 2003
)
1.23
"Alfentanil is a potent opioid used in clinical anaesthetic practice and is also metabolized by P4503A4."( Elimination of alfentanil delivered by infusion is not altered by the chronic administration of atorvastatin.
Malkan, D; McDonnell, CG; Shorten, GD; Van Pelt, FD, 2003
)
1.39
"Alfentanil is a particularly useful CYP3A probe because pupil diameter change is a surrogate for plasma concentrations, thereby affording noninvasive assessment of CYP3A."( Metabolism of alfentanil by cytochrome p4503a (cyp3a) enzymes.
Dale, O; Kharasch, ED; Klees, TM; Sheffels, P, 2005
)
1.41
"Alfentanil is a selective CYP3A probe but not a P-gp substrate."( Evaluation of first-pass cytochrome P4503A (CYP3A) and P-glycoprotein activities using alfentanil and fexofenadine in combination.
Hoffer, C; Kharasch, ED; Sheffels, P; Walker, A, 2005
)
1.27
"Alfentanil is a short-acting synthetic opioid analgesic, which is extensively metabolized, mainly by hepatic cytochrome P450 (CYP) 3A enzymes. "( Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life.
Laine, K; Leino, K; Neuvonen, PJ; Olkkola, KT; Saari, TI; Valtonen, M, 2006
)
2.03
"Alfentanil is a more effective anti-tussive agent than midazolam for outpatient fibre optic bronchoscopy."( Sedation for fibre optic bronchoscopy.
Cooper, SM; Fennerty, AG; Greig, JH; Kasimbazi, HJ; Monie, RD; Watson, B, 1995
)
1.01
"Alfentanil is a suitable analgesic drug for nitrous oxide-supplemented intravenous anaesthesia in day case surgery--provided that the appropriate requirements are taken into consideration. "( [Relevance of alfentanil as an analgesic in N20 supplemented intravenous anesthesia in ambulatory surgery].
Laufer, M; Olthoff, D; Pöhlchen, W, 1994
)
2.09
"alfentanil appears to be a suitable premedicant for short, painful procedures because it has a short duration of action and is not associated with any clinically significant side effects."( Pharmacokinetics and effects of i.m. alfentanil as premedication for day-case ophthalmic surgery in elderly patients.
Ali-Melkkilä, T; Kanto, J; Soini, H; Virkkilä, M, 1993
)
1.28
"Alfentanil is a short-acting, parenteral, opioid analgesic with a rapid onset of action."( Alfentanil-induced epileptiform activity in patients with partial epilepsy.
Cascino, GD; Lagerlund, TD; Milde, LN; O'Brien, PC; Sharbrough, FW; So, EL; Strelow, D, 1993
)
2.45
"Alfentanil is a potent and short-acting mu opioid agonist that produces both antinociceptive effects and muscle rigidity. "( Antagonist effects of beta-funaltrexamine and naloxonazine on alfentanil-induced antinociception and muscle rigidity in the rat.
Koob, GF; Negus, SS; Pasternak, GW; Weinger, MB, 1993
)
1.97
"Alfentanil is a potent, short-acting opioid agent which has been used during balanced anaesthesia in children undergoing the surgical excision of epileptic foci. "( Alfentanil mediated activation of epileptiform activity in the electrocorticogram during resection of epileptogenic foci.
Higgins, M; Keene, DL; Roberts, D; Splinter, WM; Ventureyra, E, 1997
)
3.18
"Alfentanil is an opioid analog with rapid anesthetic effect, which has been known to trigger epileptiform discharges in epilepsy patients."( Alfentanil-induced activation: a promising tool in the presurgical evaluation of temporal lobe epilepsy patients.
Galanopoulou, AS; Ragazzo, PC, 2000
)
2.47
"Alfentanil is a high potency mu opiate receptor agonist commonly used during presurgical induction of anesthesia. "( Alfentanil-induced epileptiform activity: a simultaneous surface and depth electroencephalographic study in complex partial epilepsy.
Barlow, MK; Cosgrove, GR; Houghton, KJ; Kearse, LA; Ross, J, 2001
)
3.2
"Alfentanil clearance is an excellent in vivo probe for hepatic CYP3A4 activity and drug interactions in humans."( A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans.
Kharasch, ED; Phimmasone, S, 2001
)
1.35
"Alfentanil appears to be a safe anesthetic. "( Continuous alfentanil infusion in pediatric patients undergoing general anesthesia for complete oral restoration.
Chopyk, JB; Cook, DR; Davis, PJ; Nazif, M,
)
1.96
"Alfentanil is a tertiary amine with an ionization constant of 6.5, resulting in approximately 10% ionization at physiologic pH."( Alfentanil hydrochloride: a new short-acting narcotic analgesic for surgical procedures.
Goldberg, ME; Larijani, GE, 1987
)
2.44
"Alfentanil is a potent short-acting opioid analgesic which depresses respiration and can cause cardiovascular depression. "( The pharmacokinetics and clinical effects of a low dose of alfentanil in elderly patients.
Bower, S; Dodson, ME; Kent, AP, 1988
)
1.96
"Alfentanil was found to be a safe and effective analgesic agent in short duration surgery, by reducing sympathetic responses to intubation without cardiovascular depression or compromise of postoperative recovery."( Alfentanil for short duration laparoscopic procedures.
Lee, KS; Purcell, GJ; Rae, BR; White, B, 1986
)
2.44
"Alfentanil is a tetrazole derivative of fentanyl. "( Alfentanil in anesthesia and analgesia.
Reitz, JA, 1986
)
3.16
"Alfentanil is an opioid that has been used both as a sole anesthetic and in conjunction with other inhalation anesthetics. "( Hemodynamic responses to alfentanil in halothane-anesthetized dogs.
Eisele, JH; Kien, ND; Reitan, JA; White, DA; Wu, CH, 1986
)
2.02
"Alfentanil is a short acting opioid that has an established place in anaesthesia. "( Alfentanil infusions in patients requiring intensive care.
Bodenham, A; Park, GR, 1988
)
3.16
"Alfentanil is a valuable adjunct to anaesthesia for day-case surgery and for short, painful procedures."( Use of alfentanil in short anaesthetic procedures.
Collins, KM; Plantevin, OM, 1985
)
1.45

Effects

Alfentanil has a shorter duration of action and is claimed to have less postoperative ventilatory depression than fentanyl. It has a lower total body clearance, smaller volume of distribution, and shorter half-life than fentanyl and sufentanIL.

Alfentanil has many of those ideal properties needed of a sedative drug in the ITU. It is a potent ventilatory depressant, has a high therapeutic ratio, minimal immunological or metabolic effects, and an appropriate kinetic profile.

ExcerptReferenceRelevance
"Alfentanil has a short duration action which did not markedly increase with increasing dose in mice. "( Alfentanil: a study of its analgesic activity and interactions with morphine in the mouse.
Brown, JH; Pleuvry, BJ; Williams, JG, 1982
)
3.15
"Alfentanil has a shorter duration of action and is claimed to have less postoperative ventilatory depression than fentanyl."( New narcotics in anesthesia.
Borel, JD, 1983
)
0.99
"Alfentanil has a lower total body clearance, smaller volume of distribution, and shorter half-life than fentanyl and sufentanil."( Alfentanil in anesthesia and analgesia.
Reitz, JA, 1986
)
2.44
"Alfentanil has a different pharmacokinetic and pharmacodynamic profile compared to fentanyl. "( The clinical pharmacology of alfentanil.
Stanski, DR, 1987
)
2.01
"Alfentanil itself has no proconvulsive effect in combination with etomidate."( Double-blind placebo controlled study of the effects of etomidate-alfentanil anesthesia in electroconvulsive therapy.
Bruijn, JA; Groenland, TH; Kusuma, A; Mulder, PG; van den Broek, WW, 2004
)
1.28
"Alfentanil has a short duration action which did not markedly increase with increasing dose in mice. "( Alfentanil: a study of its analgesic activity and interactions with morphine in the mouse.
Brown, JH; Pleuvry, BJ; Williams, JG, 1982
)
3.15
"Alfentanil has a shorter duration of action and is claimed to have less postoperative ventilatory depression than fentanyl."( New narcotics in anesthesia.
Borel, JD, 1983
)
0.99
"Alfentanil has the most rapid analgesic onset and time to peak effect as well as the shortest distribution and elimination half-lives."( Clinical pharmacokinetics of alfentanil, fentanyl and sufentanil. An update.
Scholz, J; Schulz, M; Steinfath, M, 1996
)
1.31
"Alfentanil clearance has previously been shown to exhibit an important interindividual variability, which was not observed for fentanyl or sufentanil."( Possible involvement of multiple cytochrome P450S in fentanyl and sufentanil metabolism as opposed to alfentanil.
Beaune, P; Brazier, JL; Buronfosse, T; Désage, M; Guitton, J; Lepape, A, 1997
)
1.23
"Alfentanil has the fastest onset of action, followed by sufentanil and then fentanyl."( Clinical uses of fentanyl, sufentanil, and alfentanil.
Clotz, MA; Nahata, MC, 1991
)
1.27
"Alfentanil has the shortest elimination half-time of the narcotics used in anaesthesia, suggesting that it should be the least likely to cause postoperative respiratory depression."( Apnoea and unconsciousness after apparent recovery from alfentanil-supplemented anaesthesia.
Hudson, RJ, 1990
)
1.25
"Alfentanil has a lower total body clearance, smaller volume of distribution, and shorter half-life than fentanyl and sufentanil."( Alfentanil in anesthesia and analgesia.
Reitz, JA, 1986
)
2.44
"Alfentanil has a different pharmacokinetic and pharmacodynamic profile compared to fentanyl. "( The clinical pharmacology of alfentanil.
Stanski, DR, 1987
)
2.01
"Alfentanil has many of those ideal properties needed of a sedative drug in the ITU--its use is associated with marked cardiovascular stability, it is a potent ventilatory depressant, has a high therapeutic ratio, minimal immunological or metabolic effects, and has an appropriate kinetic profile (low liposolubility, small volume of distribution, short half-life)."( Is alfentanil by infusion useful for sedation on the ITU?
Fisher, A; Sear, JW; Summerfield, RJ, 1987
)
1.62

Actions

Alfentanil may cause less intense respiratory depression than equianalgesic doses of fentanyl. The alfentanIL-induced increase in thiopental potency for the antinociceptive effect was greater than that for the hypnotic effect.

ExcerptReferenceRelevance
"Both alfentanil and fentanyl activate epileptiform activity in patients with temporal lobe epilepsy. "( Intraoperative localization of an epileptogenic focus with alfentanil and fentanyl.
Burke, SJ; El Beheiry, H; Lozano, AM; Manninen, PH; Wennberg, R, 1999
)
1.06
"The alfentanil-induced increase in thiopental potency for the antinociceptive effect was greater than that for the hypnotic effect (75% vs 36%, p = 0.02)."( Effect of alfentanil on hypnotic and antinociceptive components of thiopental sodium anesthesia.
Bradley, EL; Kissin, I; Mehta, D,
)
1.01
"Alfentanil may cause less intense respiratory depression than equianalgesic doses of fentanyl."( Alfentanil in anesthesia and analgesia.
Reitz, JA, 1986
)
2.44

Treatment

Alfentanil pre-treatment allowed intubation in 93% of patients compared to 60% in each of the groups pre-treated with lignocaine or saline. The drug did not produce any receptor protection.

ExcerptReferenceRelevance
"Alfentanil pre-treatment allowed intubation in 93% of patients compared to 60% in each of the groups pre-treated with lignocaine or saline."( Intubation with propofol: evaluation of pre-treatment with alfentanil or lignocaine.
Carter, JA; Goldhill, DR; Grange, CS; Meikle, R; Suresh, D, 1993
)
1.25
"Treatment with alfentanil did not produce any receptor protection."( Sufentanil and alfentanil cause vasorelaxation by mechanisms independent of the endothelium.
Iwanov, V; Karasawa, F; Moulds, RF, 1993
)
0.98
"Pretreatment with alfentanil also resulted in a significantly higher success rate during the first attempt at inserting the laryngeal mask airway compared with Group P (Group P 58%, Group A5 96%, Group A10 94%)."( Alfentanil co-induction for laryngeal mask insertion.
Ang, S; Cheong, KF; Ng, TI, 1999
)
2.07
"Pretreatment with alfentanil significantly diminished haemodynamic responses to tracheal intubation."( Injection pain, cardiovascular changes and recovery following induction of anaesthesia with propofol in combination with alfentanil or lignocaine in children.
Hiller, A; Saarnivaara, L, 1992
)
0.81

Toxicity

Midazolam + alfentanil and propofol are equally safe for sedation during bronchoscopy. Adverse respiratory events were significantly less frequent in the rocuronium group.

ExcerptReferenceRelevance
" Intubation conditions 60 sec after administration of muscle relaxant and immediate cardiovascular disturbances or adverse events during the hospital stay were noted by blinded observers."( Comparison of neuromuscular effects, efficacy and safety of rocuronium and atracurium in ambulatory anaesthesia.
Estafanous, FG; Knapik, AL; Maurer, WG; Whalley, DG, 1998
)
0.3
" The incidence of adverse events and the cardiovascular profiles for the two drugs were similar, although one patient receiving atracurium experienced transient flushing of the head and neck."( Comparison of neuromuscular effects, efficacy and safety of rocuronium and atracurium in ambulatory anaesthesia.
Estafanous, FG; Knapik, AL; Maurer, WG; Whalley, DG, 1998
)
0.3
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" No respiratory (respiratory rate/transcutaneous PCO(2)) or cardiovascular (heart rate/blood pressure) adverse events were recorded at any time during any of the PCS procedures."( Patient controlled sedation using a standard protocol for dressing changes in burns: patients' preference, procedural details and a preliminary safety evaluation.
Bak, Z; Nilsson, A; Sjöberg, F; Steinvall, I, 2008
)
0.35
"The aim of this study was to compare intubating conditions and adverse events after sevoflurane induction in infants, with or without the use of rocuronium or alfentanil."( Intubating conditions and adverse events during sevoflurane induction in infants.
Devys, JM; Donnette, FX; Dureau, P; Le Bigot, P; Mourissoux, G; Plat, R; Plaud, B; Schauvliège, F, 2011
)
0.57
" The secondary outcome criteria were respiratory (Sp(O₂) <90%, laryngospasm, closed vocal cords preventing intubation, bronchospasm) and haemodynamic adverse events (heart rate and mean arterial pressure variations ≥30% control value)."( Intubating conditions and adverse events during sevoflurane induction in infants.
Devys, JM; Donnette, FX; Dureau, P; Le Bigot, P; Mourissoux, G; Plat, R; Plaud, B; Schauvliège, F, 2011
)
0.37
" Adverse respiratory events were significantly less frequent in the rocuronium group: 0% vs 33% in the placebo group and 30% in the alfentanil group (P=0."( Intubating conditions and adverse events during sevoflurane induction in infants.
Devys, JM; Donnette, FX; Dureau, P; Le Bigot, P; Mourissoux, G; Plat, R; Plaud, B; Schauvliège, F, 2011
)
0.57
"3 mg kg⁻¹ rocuronium to 8% sevoflurane improved intubating conditions and decreased the frequency of respiratory adverse events."( Intubating conditions and adverse events during sevoflurane induction in infants.
Devys, JM; Donnette, FX; Dureau, P; Le Bigot, P; Mourissoux, G; Plat, R; Plaud, B; Schauvliège, F, 2011
)
0.37
"Midazolam + alfentanil and propofol are equally safe for sedation during bronchoscopy."( Propofol safety in bronchoscopy: prospective randomized trial using transcutaneous carbon dioxide tension monitoring.
Carmi, U; Fruchter, O; Kramer, MR; Rosengarten, D; Zemtzov, D, 2011
)
0.75
" Adverse events, drug dose, induction, procedure and recovery time, cough severity, and propofol injection related pain were recorded."( The safety and efficacy of alfentanil-based induction in bronchoscopy sedation: A randomized, double-blind, controlled trial.
Hsieh, CH; Kuo, CH; Kuo, HP; Lin, SM; Lin, TY; Lo, YL; Wang, TY, 2016
)
0.73
" The discharge time, consumption of propofol and opioid, adverse events, diagnostic accuracy, and sensitivity and specificity for malignancy, were compared."( Efficacy and safety of remifentanil for endoscopic ultrasound-guided tissue acquisition: a single center retrospective study.
Huang, CH; Huang, HH; Lin, PL; Lin, YJ; Wang, YC, 2022
)
0.72
" The consumption of propofol, adverse events, diagnostic accuracy, sensitivity, and specificity for malignancy in the alfentanil group were not significantly different from those in the remifentanil group."( Efficacy and safety of remifentanil for endoscopic ultrasound-guided tissue acquisition: a single center retrospective study.
Huang, CH; Huang, HH; Lin, PL; Lin, YJ; Wang, YC, 2022
)
0.93
" During endoscopic procedures, remimazolam is an effective and safe sedative procedure."( Efficacy and Safety of the Remimazolam-Alfentanil Combination for Sedation During Gastroscopy: A Randomized, Double-blind, Single-center Controlled Trial.
Cheng, Y; Fang, Q; Fang, X; He, H; Hu, Y; Shi, W; Shuai, Y; Wang, Z; Xu, X; Zhang, J; Zhang, Y, 2022
)
0.99
" Changes in vital signs and the appearance of adverse events were used to assess the safety of drug combinations."( Efficacy and Safety of the Remimazolam-Alfentanil Combination for Sedation During Gastroscopy: A Randomized, Double-blind, Single-center Controlled Trial.
Cheng, Y; Fang, Q; Fang, X; He, H; Hu, Y; Shi, W; Shuai, Y; Wang, Z; Xu, X; Zhang, J; Zhang, Y, 2022
)
0.99
" The sedation strategy of remimazolam-alfentanil has noninferior efficacy, fewer adverse effects, and a better postoperative recovery process than propofol-alfentanil for patients undergoing gastroscopy."( Efficacy and Safety of the Remimazolam-Alfentanil Combination for Sedation During Gastroscopy: A Randomized, Double-blind, Single-center Controlled Trial.
Cheng, Y; Fang, Q; Fang, X; He, H; Hu, Y; Shi, W; Shuai, Y; Wang, Z; Xu, X; Zhang, J; Zhang, Y, 2022
)
1.26
" The primary outcome was the incidence of intraoperative cardiopulmonary adverse events (a composite outcome of hypotension, bradycardia and hypoxemia)."( Cardiopulmonary Adverse Events of Remimazolam versus Propofol During Cervical Conization: A Randomized Controlled Trial.
Huang, Z; Ma, L; Mu, X; Nie, H; Wang, L; Wang, Y; Zheng, Z, 2023
)
0.91
"The incidence of intraoperative cardiopulmonary adverse events was 45 (44."( Cardiopulmonary Adverse Events of Remimazolam versus Propofol During Cervical Conization: A Randomized Controlled Trial.
Huang, Z; Ma, L; Mu, X; Nie, H; Wang, L; Wang, Y; Zheng, Z, 2023
)
0.91
"In patients who underwent cold knife cervical conization, remimazolam-alfentanil anesthesia was associated with a reduced incidence of intraoperative cardiopulmonary adverse events compared with propofol-alfentanil anesthesia."( Cardiopulmonary Adverse Events of Remimazolam versus Propofol During Cervical Conization: A Randomized Controlled Trial.
Huang, Z; Ma, L; Mu, X; Nie, H; Wang, L; Wang, Y; Zheng, Z, 2023
)
1.14
"This meta-study found that current evidence indicates that alfentanil plus propofol is better than propofol alone for painless gastrointestinal endoscopy and is associated with a lower incidence of adverse reactions."( Efficacy and safety of alfentanil plus propofol versus propofol only in painless gastrointestinal endoscopy: A meta-analysis.
Li, J; Shi, X; Yang, H; Yang, L, 2023
)
1.46

Pharmacokinetics

The purpose of the present investigation was to quantify rapid functional adaptation in the concentration-pharmacological effect relationship of alfentanil in rats using quantitative EEG parameters as a pharmacodynamic endpoint. The population pharmacokinetic parameters describing the pl were constructed. Scaling the pharmacokinetics parameters to cardiac output, heart rate, and plasma alfENTanil concentration significantly improved the model.

ExcerptReferenceRelevance
"We studied 40 patients undergoing body surface surgery in a double-blind manner to compare the pharmacodynamic stability of either mixed or separate infusions of propofol and alfentanil."( Pharmacodynamic stability of a mixture of propofol and alfentanil.
Glen, JB; Kenny, GN; Taylor, IN, 1992
)
0.72
"This work deals with the pharmacodynamic problem of relating a drug effect E(t) to an observable pharmacokinetic (PK) predictor variable r(t), which may be a venous and/or arterial drug level, some other PK variable, or a drug infusion scheme."( Pharmacodynamic system analysis of the biophase level predictor and the transduction function.
Modi, NB; Veng-Pedersen, P, 1992
)
0.28
" The elimination half-life (t1/2 beta) was 21."( The pharmacokinetics and locomotor activity of alfentanil in the horse.
Black, WD; Claxton, JM; Pascoe, PJ; Sansom, RE, 1991
)
0.54
"Fentanyl, alfentanil, and sufentanil have important pharmacokinetic and pharmacodynamic differences."( Pharmacokinetics, pharmacodynamics, and rational opioid selection.
Shafer, SL; Varvel, JR, 1991
)
0.68
"8 min) and elimination half-life (47."( Alfentanil pharmacokinetics in piglets with increased intra-abdominal pressure.
Cook, DR; Davis, PJ; Roeber, CM; Stiller, RL, 1991
)
1.72
" There were no significant correlations between the pharmacokinetic variables and the duration of aortic cross-clamping, the duration of surgery, or the rate or total volume of IV fluids infused intraoperatively."( Alfentanil pharmacokinetics in patients undergoing abdominal aortic surgery.
Burgess, PM; Hudson, RJ; Rosenbloom, M; Thomson, IR, 1991
)
1.72
" In dogs, compared with rabbits and sheep, the first distribution half-life was longer, probably because of pronounced drug-induced bradycardia (mean +/- SD, 48 +/- 21 beats/min)."( Comparative study of the pharmacokinetics of alfentanil in rabbits, sheep, and dogs.
Benthuysen, JA; Ilkiw, JE; McNeal, D, 1991
)
0.54
"min-1), or effective half-life (455 +/- 111 min vs."( Influence of gestational age on pharmacokinetics of alfentanil in neonates.
Cicco, R; Cook, DR; Davis, PJ; Guthrie, RD; Killian, A; Stiller, RL, 1990
)
0.53
" The method employs a computer-controlled infusion pump and an algorithm that utilizes individual subject pharmacokinetic parameters predetermined with tailoring bolus opioid doses."( Steady-state infusions of opioids in human volunteers. I. Pharmacokinetic tailoring.
Bjurstrom, R; Chapman, CR; Donaldson, G; Hill, HF; Jacobson, R; Saeger, L, 1990
)
0.28
"This study assessed the pharmacokinetic and pharmacodynamic behaviour of alfentanil during and after coronary artery bypass grafting (CABG)."( Pharmacokinetics of alfentanil and clinical responses during cardiac surgery.
Donati, F; Patel, YC; Ramsay, JG; Robbins, GR; Srikant, CB; Whalley, DG; Wynands, JE, 1990
)
0.83
" Pharmacokinetic differences do not explain the disparity seen in the time courses of EEG drug effect."( Understanding pharmacokinetics and pharmacodynamics through computer stimulation: I. The comparative clinical profiles of fentanyl and alfentanil.
Ebling, WF; Lee, EN; Stanski, DR, 1990
)
0.48
"The application of population pharmacokinetic analysis has received increasing attention in the last few years."( Evaluation of population (NONMEM) pharmacokinetic parameter estimates.
Maitre, PO; Stanski, DR; Vozeh, S, 1990
)
0.28
" recently evaluated the accuracy of a set of previously determined population pharmacokinetic parameters for the opioid alfentanil using data from an earlier study in which the drug had been administered using a computer-controlled infusion pump (CCIP)."( The prospective use of population pharmacokinetics in a computer-driven infusion system for alfentanil.
Buschman, A; Johnson, MD; Philip, BK; Raemer, DB; Shafer, SL; Stein, DA; Varvel, JR, 1990
)
0.71
" Though both volume of distribution and elimination half-life increased in the posttransplantation period, only the decrease in clearance was statistically significant."( Effects of cholestatic hepatic disease and chronic renal failure on alfentanil pharmacokinetics in children.
Brandom, BW; Cook, DR; Davis, JE; Davis, PJ; Scierka, AM; Stiller, RL, 1989
)
0.51
" Pharmacokinetic parameters were estimated by a model-independent approach and by curve-fitting."( Pharmacokinetics of alfentanil during and after a fixed rate infusion.
Crul, J; Gasparini, R; Heykants, J; Noorduin, H; Van Beem, H; Van Egmond, J; Van Peer, A; Woestenborghs, R, 1989
)
0.6
" The pharmacokinetic profile of alfentanil was determined in 6 premature infants requiring sedation for medical management or analgesia for stressful intensive-care procedures."( Pharmacokinetics of alfentanil in newborn premature infants and older children.
Cook, DR; Davis, PJ; Guthrie, RD; Killian, A; Scierka, AM; Stiller, RL, 1989
)
0.88
"The pharmacokinetic and pharmacodynamic properties of alfentanil were studied in 64 surgical patients."( Pharmacokinetics and pharmacodynamics of alfentanil infusions during general anesthesia.
Shafer, A; Sung, ML; White, PF, 1986
)
0.79
" The elderly can show greater sensitivity to opioid drugs which may be related to pharmacokinetic differences."( The pharmacokinetics and clinical effects of a low dose of alfentanil in elderly patients.
Bower, S; Dodson, ME; Kent, AP, 1988
)
0.52
" Elimination half-life and plasma clearance were similar in both groups."( Pharmacokinetics of alfentanil in chronic renal failure.
Chauvin, M; Duvaldestin, P; Lebrault, C; Levron, JC, 1987
)
0.6
" The optimal pharmacokinetic model for alfentanil was an open two-compartment model."( A comparison of alfentanil pharmacokinetics in children and adults.
Lepaul, M; Levron, JC; Loose, JP; Mac Gee, K; Meistelman, C; Saint-Maurice, C, 1987
)
0.89
"The population pharmacokinetic parameters describing the plasma concentration versus time profile of alfentanil in patients undergoing general anesthesia were determined from 614 plasma concentration measurements collected in four previously reported studies with a total of 45 patients."( Population pharmacokinetics of alfentanil: the average dose-plasma concentration relationship and interindividual variability in patients.
Heykants, J; Maitre, PO; Stanski, DR; Thomson, DA; Vozeh, S, 1987
)
0.77
" The pharmacokinetic and pharmacodynamic components of each patient's dose-response relationship were evaluated simultaneously."( Decreased fentanyl and alfentanil dose requirements with age. A simultaneous pharmacokinetic and pharmacodynamic evaluation.
Scott, JC; Stanski, DR, 1987
)
0.58
" Pharmacokinetic values were independent of dose."( The pharmacokinetics of alfentanil in children.
Goresky, GV; Koren, G; Sabourin, MA; Sale, JP; Strunin, L, 1987
)
0.58
" Recently, the authors completed a population pharmacokinetic analysis of the new opioid alfentanil using the computer program NONMEM."( Evaluating the accuracy of using population pharmacokinetic data to predict plasma concentrations of alfentanil.
Ausems, ME; Maitre, PO; Stanski, DR; Vozeh, S, 1988
)
0.71
" A pharmacokinetic basis is given for alfentanil infusion schemes in patients undergoing routine surgery."( The pharmacokinetic basis of alfentanil infusion.
Geerts, P; Heykants, J; Noorduin, H; Vanden Bussche, G, 1987
)
0.84
"58 litre kg-1, resulting in a terminal half-life of 112 min."( Pharmacokinetics of alfentanil in total i.v. anaesthesia.
Hartvig, P; Nilsson, A; Persson, MP, 1988
)
0.6
" Pharmacokinetic parameters were similar in the three subjects and were in the same range as those reported for volunteers."( Alfentanil pharmacokinetics and metabolism in humans.
Hendrickx, J; Heykants, J; Lauwers, W; Meuldermans, W; Van Craeyvelt, H; Van der Aa, P; Van Peer, A; Vanden Bussche, G; Woestenborghs, R, 1988
)
1.72
" To accurately relate EEG changes to serum narcotic concentrations, a pharmacodynamic model (inhibitory sigmoid Emax) was combined with a pharmacokinetic model that incorporated an "effect" compartment."( EEG quantitation of narcotic effect: the comparative pharmacodynamics of fentanyl and alfentanil.
Ponganis, KV; Scott, JC; Stanski, DR, 1985
)
0.49
" The kinetics of the analgesic can be described by a two-compartment model; the elimination half-life has a mean value of 64."( Pharmacokinetic data analysis of alfentanil after multiple injections and etomidate-infusion in patients undergoing orthopedic surgery.
Abel, J; Freye, E; Haag, W; Hartung, E; Klatte, A; Richter, O, 1985
)
0.55
" groups showed the same pharmacokinetic pattern."( Clinical assessment and plasma pharmacokinetics associated with intramuscular or extradural alfentanil.
Chauvin, M; Levron, JC; Perrin, D; Salbaing, J; Viars, P, 1985
)
0.49
"The accuracy of using average alfentanil pharmacokinetic data in a computer assisted infusion pump (TIAC) to predict alfentanil plasma concentrations was tested in 35 patients (divided into three groups) receiving alfentanil and nitrous oxide in oxygen anaesthesia for lower and upper abdominal surgery."( An evaluation of the accuracy of pharmacokinetic data for the computer assisted infusion of alfentanil.
Ausems, ME; Hug, CC; Stanski, DR, 1985
)
0.78
"In 7 patients (ASA class I and II) the pharmacokinetic behaviour after bolus injection of alfentanyl was investigated."( [Clinical pharmacokinetics of alfentanyl (author's transl)].
Schüttler, J; Stoeckel, H, 1982
)
0.26
" For both analgesics, the pharmacokinetic profile in man could be described by a three-compartment model."( Radioimmunoassay of the new opiate analgesics alfentanil and sufentanil. Preliminary pharmacokinetic profile in man.
Hendriks, R; Heykants, J; Michiels, M, 1983
)
0.52
" Recent developments in analytical techniques have allowed pharmacokinetic studies and these have confirmed this opinion; fentanyl is rightly regarded as having a redistribution-limited duration of action after single or infrequent doses (analogous to thiopentone)."( Clinical pharmacokinetics of fentanyl and its newer derivatives.
Mather, LE,
)
0.13
" The distribution half-life (mean +/- SD) (7."( Pharmacokinetics of the infusion of alfentanil in man.
Booij, LH; Braak, GJ; Crul, JF; Fragen, RJ; Heykants, J; Vree, TB, 1983
)
0.54
" The performance of computer-controlled infusion devices is highly dependent on how well the implemented pharmacokinetic parameter set matches the pharmacokinetics of the patient."( Performance of computer-controlled infusion of propofol: an evaluation of five pharmacokinetic parameter sets.
Bovill, JG; Burm, AG; Engbers, FH; Vletter, AA; Vuyk, J, 1995
)
0.29
" Pharmacokinetic modeling estimated a set of parameters for a simple three-compartment model with a median absolute weighted residual of 18."( Pharmacokinetics of computer-controlled alfentanil administration in children undergoing cardiac surgery.
Brand, SC; Engstrom, R; Fiset, P; Fitzgerald, D; Hsu, F; Mathers, L; Shafer, SL, 1995
)
0.56
" The flexible CPB-adjusted pharmacokinetic model could be used for modeling any drug with linear pharmacokinetics given in the context of CPB."( Pharmacokinetics of computer-controlled alfentanil administration in children undergoing cardiac surgery.
Brand, SC; Engstrom, R; Fiset, P; Fitzgerald, D; Hsu, F; Mathers, L; Shafer, SL, 1995
)
0.56
"This pharmacokinetic study demonstrates a rapid rise in plasma concentrations, as well as a high bioavailability, following the intranasal administration of alfentanil."( Pharmacokinetics of intranasal alfentanil.
Boerger, N; Meissner, W; Schwagmeier, R; Striebel, HW, 1995
)
0.77
" The purpose of this study was to characterize the pharmacodynamic interaction between propofol and alfentanil for several clinically relevant end points."( The pharmacodynamic interaction of propofol and alfentanil during lower abdominal surgery in women.
Bovill, JG; Burm, AG; Engbers, FH; Lim, T; Vletter, AA; Vuyk, J, 1995
)
0.76
"We defined the pharmacodynamic interaction between propofol and alfentanil for suppression of responses to perioperative stimuli during lower abdominal surgery."( The pharmacodynamic interaction of propofol and alfentanil during lower abdominal surgery in women.
Bovill, JG; Burm, AG; Engbers, FH; Lim, T; Vletter, AA; Vuyk, J, 1995
)
0.79
" However, the elimination half-life of alfentanil (t1/2 beta) (mean, 95% confidence interval) did not differ significantly between the normothermic (134 min, range 104-172), hypothermic (143 min, range 111-184), and nonbypass (111 min, range 86-142) groups."( The pharmacokinetics of alfentanil after normothermic and hypothermic cardiopulmonary bypass.
Doré, CJ; Dunne, N; Gillbe, C; Macrae, D; Mehta, R; Petros, A; Van Peer, A, 1995
)
0.87
"The objectives of this investigation were to characterize the disposition of fentanyl and alfentanil in 14 tissues in the rat, and to create physiological pharmacokinetic models for these opioids that would be scalable to man."( Comparative physiological pharmacokinetics of fentanyl and alfentanil in rats and humans based on parametric single-tissue models.
Björkman, S; Ebling, WF; Stanski, DR; Wada, DR, 1994
)
0.75
"34 L/kg, resulting in a blood elimination half-life of 144 +/- 46 minutes."( Clinical pharmacokinetics of propofol given as a constant-rate infusion and in combination with epidural blockade.
Hartvig, P; Nilsson, A; Persson, PM; Wessén, A,
)
0.13
"We could not show any statistically significant influence of an epidural blockade on the pharmacokinetic parameters of propofol."( Clinical pharmacokinetics of propofol given as a constant-rate infusion and in combination with epidural blockade.
Hartvig, P; Nilsson, A; Persson, PM; Wessén, A,
)
0.13
" Estrogen replacement therapy (ERT) did not restore POM pharmacokinetic parameters to PRM values."( Menopause: pharmacodynamics and pharmacokinetics.
Benet, LZ; Gustavson, LE,
)
0.13
" We investigated the role of each of these primary pharmacokinetic parameters to determine values of each that would contribute to rapid recovery after various dosing schemes."( Pharmacokinetic parameters relevant to recovery from opioids.
Shafer, SL; Youngs, EJ, 1994
)
0.29
" Set I predicted the change in plasma concentration of each drug after a bolus if each pharmacokinetic parameter were independently increased by 5%."( Pharmacokinetic parameters relevant to recovery from opioids.
Shafer, SL; Youngs, EJ, 1994
)
0.29
"This study proposes qualitative guidelines for pharmacokinetic properties desirable in anesthetic drugs."( Pharmacokinetic parameters relevant to recovery from opioids.
Shafer, SL; Youngs, EJ, 1994
)
0.29
"Classical pharmacokinetic models used in computer-controlled infusion pumps (CCIPs) assume instantaneous mixing of drug in blood; however, the average recirculation time of blood in man is approximately one minute."( The hybrid model: a new pharmacokinetic model for computer-controlled infusion pumps.
Wada, DR; Ward, DS, 1994
)
0.29
"The mean (+/- SD) steady-state volume of distribution, total plasma clearance, elimination half-life and mean residence time, derived from the unlabeled alfentanil concentration-time data, were 43."( Pharmacokinetics of alfentanil after epidural administration. Investigation of systemic absorption kinetics with a stable isotope method.
Bovill, JG; Burm, AG; Haak-van der Lely, F; Jacobs, CJ; Onkenhout, W; van den Heuvel, RP; van Kleef, JW; Vletter, AA, 1994
)
0.81
" Although several comprehensive pharmacodynamic models have been proposed, relatively few of these have attempted to assess objectively the application of the models to predict pharmacologic responses."( Validation of a variable direction hysteresis minimization pharmacodynamic approach: cardiovascular effects of alfentanil.
Modi, NB; Veng-Pedersen, P, 1994
)
0.5
" A system analysis hysteresis minimization pharmacodynamic method was developed to describe the central nervous system effects of alfentanil in rabbits."( Application of a variable direction hysteresis minimization approach in describing the central nervous system pharmacodynamic effects of alfentanil in rabbits.
Modi, NB; Veng-Pedersen, P, 1994
)
0.7
" It is pointed out that NN may also be particularly suitable to deal with pharmacokinetic (PK) and pharmacodynamic (PD) systems, especially in cases such as multivariate PK/PD population kinetics when the systems are so complex that modeling by a conventional structured model building technique is very troublesome."( Application of neural networks to pharmacodynamics.
Modi, NB; Veng-Pedersen, P, 1993
)
0.29
" The alfentanil concentrations were significantly greater in the deltoid group during the study and the mean peak concentration occurred more rapidly in this group."( Pharmacokinetics and effects of i.m. alfentanil as premedication for day-case ophthalmic surgery in elderly patients.
Ali-Melkkilä, T; Kanto, J; Soini, H; Virkkilä, M, 1993
)
1.07
" Pharmacokinetic data were derived using non-compartmental methods."( Influence of Crohn's disease on the pharmacokinetics and pharmacodynamics of alfentanil.
Bovill, JG; Burm, AG; Gesink-van der Veer, BJ; Vletter, AA, 1993
)
0.51
" Among the opioids currently available, alfentanil seems to be particularly suited to these goals because of its pharmacokinetic and pharmacodynamic characteristics."( Alfentanil pharmacokinetics in cardiac surgical patients.
Burm, AG; de Lange, S; Hug, CC, 1994
)
2
" A two-compartment pharmacokinetic model adequately characterized the plasma concentration profiles of alfentanil for 31 of 34 patients."( Pharmacokinetics of alfentanil administered at a variable rate during three types of surgery.
Ausems, ME; Burm, AG; Spierdijk, J; Stanski, DR, 1993
)
0.82
" The study comprised both a validation of published pharmacokinetic data sets and the definition of the minimum effective analgesic concentrations after major orthopedic surgery."( Computer-controlled infusion of alfentanil for postoperative analgesia. A pharmacokinetic and pharmacodynamic evaluation.
Bovill, JG; Burm, AG; Engbers, FH; Lemmens, HJ; van den Nieuwenhuyzen, MC; van Kleef, JW; Vletter, AA, 1993
)
0.57
"The bias and inaccuracy of the implemented pharmacokinetic data set were examined, in 20 patients who had undergone major orthopedic surgery, by determination of the median performance error (MDPE) and median absolute performance error (MDAPE)."( Computer-controlled infusion of alfentanil for postoperative analgesia. A pharmacokinetic and pharmacodynamic evaluation.
Bovill, JG; Burm, AG; Engbers, FH; Lemmens, HJ; van den Nieuwenhuyzen, MC; van Kleef, JW; Vletter, AA, 1993
)
0.57
" The study demonstrated that pharmacokinetic data sets that are useful for intraoperative CCI of alfentanil are equally valid in the postoperative phase."( Computer-controlled infusion of alfentanil for postoperative analgesia. A pharmacokinetic and pharmacodynamic evaluation.
Bovill, JG; Burm, AG; Engbers, FH; Lemmens, HJ; van den Nieuwenhuyzen, MC; van Kleef, JW; Vletter, AA, 1993
)
0.79
"Although propofol and alfentanil are given in combination in clinical practice, the pharmacodynamic interaction between these drugs has not been described."( Pharmacodynamics of alfentanil as a supplement to propofol or nitrous oxide for lower abdominal surgery in female patients.
Bovill, JG; Burm, AG; Engbers, FH; Lim, T; Vletter, AA; Vuyk, J, 1993
)
0.92
" The pharmacokinetic data were characterized by a three-compartment model with nonlinear clearance."( Pharmacodynamic model for acute tolerance development to the electroencephalographic effects of alfentanil in the rat.
Mandema, JW; Wada, DR, 1995
)
0.51
"A pilot study was conducted in 7 normal volunteers to demonstrate the feasibility of employing pharmacokinetic tailoring to achieve matching plasma opioid concentration-time curves after epidural (e."( A pharmacokinetic approach to resolving spinal and systemic contributions to epidural alfentanil analgesia and side-effects.
Brown, MC; Coda, BA; Donaldson, G; Schaffer, RL; Shen, DD, 1995
)
0.51
"3 l; steady-state distribution volume (Vdss): 499 +/- 173 l; total clearance (Cltot): 1001- +/- 150 ml/min; redistribution half-life (t1/2 gamma): 90 +/- 23 min; elimination half-life (t1/2 beta): 558 +/- 218 minutes."( Pharmacokinetics and pharmacodynamics of propofol/alfentanil infusions for sedation in ICU patients.
Frenkel, C; Heye, H; Ihmsen, H; Rommelsheim, K; Schuttler, J, 1995
)
0.54
"The population pharmacokinetic analysis of propofol/alfentanil for ICU sedation therapy revealed increased volumes of drug distribution and decreased elimination characteristics as compared to pharmacokinetic data from short-term infusions in surgical patients."( Pharmacokinetics and pharmacodynamics of propofol/alfentanil infusions for sedation in ICU patients.
Frenkel, C; Heye, H; Ihmsen, H; Rommelsheim, K; Schuttler, J, 1995
)
0.79
" Important pharmacokinetic differences between alfentanil, fentanyl and sufentanil have been shown in many reports."( Clinical pharmacokinetics of alfentanil, fentanyl and sufentanil. An update.
Scholz, J; Schulz, M; Steinfath, M, 1996
)
0.84
" Remifentanil was rapidly eliminated, with a terminal half-life of 6 min, compared with 19 min for GR90291 and alfentanil."( Comparative pharmacokinetics and pharmacodynamics of remifentanil, its principle metabolite (GR90291) and alfentanil in dogs.
Cunningham, F; Hoffman, WE; Hoke, JF; James, MK; Muir, KT, 1997
)
0.72
"This study in rats was performed to explore whether the inhibitory effect of midazolam on the development of acute tolerance to the analgesic effect of alfentanil is due to pharmacokinetic mechanisms."( Effect of midazolam on development of acute tolerance to alfentanil: the role of pharmacokinetic interactions.
Arthur, GR; Bradley, EL; Kissin, I; Lee, SS, 1997
)
0.74
" Pharmacokinetic parameters were determined by two-stage analysis using both noncompartmental and three-compartment models."( The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions.
Bowdle, A; Cox, K; Kharasch, ED; Kunze, KL; Mautz, D; Russell, M; Thummel, KE, 1997
)
0.57
" The values of the pharmacokinetic parameters were (mean +/- SE, n = 7); clearance = 53 +/- 6 ml."( Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats.
Cox, EH; Danhof, M; Tukker, EJ; Van Hemert, JG, 1997
)
0.54
"5 Hz frequency band of the electroencephalogram (EEG) was used as pharmacodynamic endpoint."( Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor.
Cox, EH; Danhof, M; Kerbusch, T; Van der Graaf, PH, 1998
)
0.3
" The aims of this study were to determine whether physiologic pharmacokinetic models for fentanyl and alfentanil, based on data from rats, could predict plasma concentrations of these opioids in humans and to determine how changes in physiology would influence the predictions of their disposition."( Application of physiologic models to predict the influence of changes in body composition and blood flows on the pharmacokinetics of fentanyl and alfentanil in patients.
Björkman, S; Stanski, DR; Wada, DR, 1998
)
0.72
"The predictions of the models were tested against plasma concentration data from published pharmacokinetic studies."( Application of physiologic models to predict the influence of changes in body composition and blood flows on the pharmacokinetics of fentanyl and alfentanil in patients.
Björkman, S; Stanski, DR; Wada, DR, 1998
)
0.5
" When the observed TPEP effect was plotted versus the alfentanil blood concentration no hysteresis or proteresis was observed, and the two could directly be related to each other on the basis of the sigmoidal Emax pharmacodynamic model."( Pharmacokinetic-pharmacodynamic modelling of the analgesic effect of alfentanil in the rat using tooth pulp evoked potentials.
Cox, EH; Danhof, M; Langemeijer, MW, 1998
)
0.78
" A loading dose based on the Vd at the tmax will accurately achieve the concentration at the tmax without unexpected adverse effects."( Determination of the distribution volume that can be used to calculate the intravenous loading dose.
Drover, DR; Lemmens, HJ; Wada, DR, 1998
)
0.3
" The purpose of the present investigation was to quantify rapid functional adaptation in the concentration-pharmacological effect relationship of alfentanil in rats using quantitative EEG parameters as a pharmacodynamic endpoint."( Pharmacokinetic-pharmacodynamic modelling of the EEG effect of alfentanil in rats: assessment of rapid functional adaptation.
Cox, EH; Danhof, M; Kuipers, JA, 1998
)
0.74
"Cardiac output (CO) is likely to influence the pharmacokinetics of anesthetic drugs and should be accounted for in pharmacokinetic models."( Recirculatory and compartmental pharmacokinetic modeling of alfentanil in pigs: the influence of cardiac output.
Boer, F; Bovill, JG; Burm, AG; Kuipers, JA; Olieman, W; Olofsen, E; Vletter, AA, 1999
)
0.55
" Therefore, accounting for CO enhances the predictive value of pharmacokinetic models of alfentanil."( Recirculatory and compartmental pharmacokinetic modeling of alfentanil in pigs: the influence of cardiac output.
Boer, F; Bovill, JG; Burm, AG; Kuipers, JA; Olieman, W; Olofsen, E; Vletter, AA, 1999
)
0.77
" A mamillary two-compartment model was fitted to the pharmacokinetic data."( Pharmacokinetic-pharmacodynamic modeling of the respiratory depressant effect of alfentanil.
Bouillon, T; Garstka, G; Heimbach, D; Hoeft, A; Schmidt, C; Schwilden, H; Stafforst, D, 1999
)
0.53
" The following pharmacodynamic parameters were estimated (population means and interindividual variability): EC50, 60."( Pharmacokinetic-pharmacodynamic modeling of the respiratory depressant effect of alfentanil.
Bouillon, T; Garstka, G; Heimbach, D; Hoeft, A; Schmidt, C; Schwilden, H; Stafforst, D, 1999
)
0.53
" Using SAAM II pharmacokinetic modeling software (SAAM Institute, University of Washington, Seattle, WA), the data were fit to a 16-compartment model that was divided into four spinal levels, each of which consisted of a caternary arrangement of four compartments representing the spinal cord, cerebrospinal fluid, epidural space, and epidural fat."( Comparative spinal distribution and clearance kinetics of intrathecally administered morphine, fentanyl, alfentanil, and sufentanil.
Arends, RH; Bernards, CM; Shen, DD; Ummenhofer, WC, 2000
)
0.52
"The four opioids studied demonstrate markedly different pharmacokinetic behavior, which correlates well with their pharmacodynamic behavior."( Comparative spinal distribution and clearance kinetics of intrathecally administered morphine, fentanyl, alfentanil, and sufentanil.
Arends, RH; Bernards, CM; Shen, DD; Ummenhofer, WC, 2000
)
0.52
"The pharmacodynamic differences in time to onset and dissipation of effect of sufentanil, fentanyl, and alfentanil probably result from different rates of blood-brain equilibration."( Pharmacokinetics of human cerebral opioid extraction: a comparative study on sufentanil, fentanyl, and alfentanil in a patient after severe head injury.
Göbel, L; Gruber, M; Hoerauf, KH; Metz, C; Taeger, K, 2000
)
0.74
"5 Hz frequency band of the EEG as pharmacodynamic endpoint."( Pharmacokinetic-pharmacodynamic analysis of the EEG effect of alfentanil in rats following beta-funaltrexamine-induced mu-opioid receptor "knockdown" in vivo.
Cox, E; Danhof, M; Garrido, M; Gubbens-Stibbe, J; IJzerman, A; Künzel, D; Tukker, E; van der Graaf, PH; von Frijtag, J, 2000
)
0.55
" Nonlinear mixed-effects population pharmacokinetic models examining the influence of propofol and mean arterial pressure were constructed."( Propofol alters the pharmacokinetics of alfentanil in healthy male volunteers.
Bovill, JG; Burm, AG; Mertens, MJ; Olofsen, E; Vuyk, J, 2001
)
0.58
" Scaling the pharmacokinetic parameters to the mean arterial pressure instead of propofol improved the model."( Propofol alters the pharmacokinetics of alfentanil in healthy male volunteers.
Bovill, JG; Burm, AG; Mertens, MJ; Olofsen, E; Vuyk, J, 2001
)
0.58
" We determined the pharmacokinetics of ketamine and alfentanil, alone and together, in three groups of adult male rats, to assess any pharmacokinetic interaction."( Concurrent ketamine and alfentanil administration: pharmacokinetic considerations.
Edwards, SR; Mather, LE; Minto, CF, 2002
)
0.87
" Pharmacokinetic parameters were determined by noncompartmental analysis."( Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil.
Feldman, J; Ibrahim, AE; Karim, A; Kharasch, ED, 2003
)
0.51
" A comparison is also presented between several methods based on animal pharmacokinetic data, using the same set of proprietary compounds, and it lends further support for the use of this method, as opposed to methods that require the gathering of pharmacokinetic data in laboratory animals."( Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY, 2004
)
0.32
" Nonlinear mixed-effects population pharmacokinetic models examining the influence of alfentanil and hemodynamic parameters on propofol pharmacokinetics were constructed."( Mixed-effects modeling of the influence of alfentanil on propofol pharmacokinetics.
Bovill, JG; Burm, AG; Mertens, MJ; Olofsen, E; Vuyk, J, 2004
)
0.81
" Scaling the pharmacokinetic parameters to cardiac output, heart rate, and plasma alfentanil concentration significantly improved the model."( Mixed-effects modeling of the influence of alfentanil on propofol pharmacokinetics.
Bovill, JG; Burm, AG; Mertens, MJ; Olofsen, E; Vuyk, J, 2004
)
0.81
"Human pharmacokinetic parameters are often predicted prior to clinical study from in vivo preclinical pharmacokinetic data."( Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
Jolivette, LJ; Ward, KW, 2005
)
0.33
" Suggested methods to improve our knowledge without performing conventional full-scale investigations include population pharmacokinetic studies, allometric scaling of drug disposition according to bodyweight and in silico prediction of pharmacokinetics."( Prediction of cytochrome p450-mediated hepatic drug clearance in neonates, infants and children : how accurate are available scaling methods?
Björkman, S, 2006
)
0.33
" Plasma concentrations of alfentanil were measured for 10 hours, and the pharmacokinetic parameters were calculated by use of noncompartmental methods."( Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life.
Laine, K; Leino, K; Neuvonen, PJ; Olkkola, KT; Saari, TI; Valtonen, M, 2006
)
0.88
" Alfentanil pharmacokinetics (plasma concentration, area under the plasma concentration-time curve from time zero to infinity [AUC(infinity(p))] and from time zero to 2 hours [AUC(2(p))], apparent volume of distribution at steady state, clearance and terminal elimination half-life [t((1/2)(p))]) and miosis pseudo-kinetic parameters [AUC(infinity)((miosis)), AUC(2)((miosis)), t((1/2))((miosis))] were determined using a noncompartmental analysis method."( Alfentanil-induced miosis as a surrogate measure of alfentanil pharmacokinetics in patients with mild and moderate liver cirrhosis.
Baririan, N; Desager, JP; Horsmans, Y; Starkel, P; Van Obbergh, L; Verbeeck, RK; Wallemacq, P, 2007
)
2.69
"Alfentanil pharmacokinetic parameters were correlated with miosis pseudo-kinetic parameters in cirrhotic patients."( Alfentanil-induced miosis as a surrogate measure of alfentanil pharmacokinetics in patients with mild and moderate liver cirrhosis.
Baririan, N; Desager, JP; Horsmans, Y; Starkel, P; Van Obbergh, L; Verbeeck, RK; Wallemacq, P, 2007
)
3.23
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" Whole-body physiologically based pharmacokinetic (WB-PBPK) modelling is a predictive technique that quantitatively relates the pharmacokinetic parameters of a drug to such (patho-)physiological conditions."( Physiology-based simulations of a pathological condition: prediction of pharmacokinetics in patients with liver cirrhosis.
Edginton, AN; Willmann, S, 2008
)
0.35
" Predictions of pharmacokinetic profiles and parameters were compared with literature data for the model compounds alfentanil, lidocaine (lignocaine), theophylline and levetiracetam."( Physiology-based simulations of a pathological condition: prediction of pharmacokinetics in patients with liver cirrhosis.
Edginton, AN; Willmann, S, 2008
)
0.56
"The predicted versus observed plasma concentration-time profiles for alfentanil and lidocaine were similar, such that the pharmacokinetic changes associated with Child-Pugh class A, B and C liver cirrhosis were adequately described."( Physiology-based simulations of a pathological condition: prediction of pharmacokinetics in patients with liver cirrhosis.
Edginton, AN; Willmann, S, 2008
)
0.58
"The aim of this study was to examine the pharmacokinetic and pharmacodynamic profile of propofol during propofol remifentanil and propofol - alfentanil anaesthesia, when monitored by SFx."( Pharmacokinetics and pharmacodynamics of propofol during propofol-alfentanil and propofol-remifentanil total intravenous anaesthesia monitored by spectral frequency index.
Bienert, A; Grabowski, T; Grzeskowiak, E; Kusza, K; Zaba, Z, 2009
)
0.79
" The remifentanil and alfentanil groups were compared in relation to pharmacokinetic and pharmacodynamic parameters of propofol and a t-test was used for statistical analysis."( Pharmacokinetics and pharmacodynamics of propofol during propofol-alfentanil and propofol-remifentanil total intravenous anaesthesia monitored by spectral frequency index.
Bienert, A; Grabowski, T; Grzeskowiak, E; Kusza, K; Zaba, Z, 2009
)
0.9
" The influence of continuous (body weight, age, blood pressure, heart rate and blood oxygenation, serum protein, the erythrocyte count, hemoglobin and hematocrit, serum creatinine and creatinine clearance) and categorical (gender and the type of opioid) covariates on the pharmacokinetic and pharmacodynamic parameters was investigated."( Influence of demographic factors, basic blood test parameters and opioid type on propofol pharmacokinetics and pharmacodynamics in ASA I-III patients.
Bienert, A; Grześkowiak, E; Kusza, K; Marciniak, R; Wiczling, P; Wolc, A; Zaba, C; Zaba, Z, 2011
)
0.37
"In open TCI and anaesthesia display systems, the choice of pharmacokinetic (PK) parameter sets of opioids is clinically relevant."( Pharmacokinetic parameter sets of alfentanil revisited: optimal parameters for use in target controlled infusion and anaesthesia display systems.
Baechtold, M; Hartwich, V; Luginbühl, M; Schnider, TW; Schumacher, PM; Sigmond, N, 2013
)
0.67
" A physiologically based pharmacokinetic (PBPK) model was developed to project the dynamics and magnitude of CYP3A4 induction in vivo from in vitro data generated with primary human hepatocytes."( Physiologically based pharmacokinetic modeling of CYP3A4 induction by rifampicin in human: influence of time between substrate and inducer administration.
Baneyx, G; Iliadis, A; Lavé, T; Meille, C; Parrott, N, 2014
)
0.4
"Allometric approaches are widely used for interspecies scaling for the prediction of pharmacokinetic (PK) parameters during drug development."( Multistep Unified Models Using Prior Knowledge for the Prediction of Drug Clearance in Neonates and Infants.
Forshee, R; Jiang, Z; Mahmood, I; Tegenge, MA, 2018
)
0.48
" Developing modelling and simulation tools, such as physiologically based pharmacokinetic (PBPK) models that incorporate developmental physiology and maturation of drug metabolism, can be used to predict drug exposure in this group of patients, and may help to optimize drug dose adjustment."( Preterm Physiologically Based Pharmacokinetic Model. Part II: Applications of the Model to Predict Drug Pharmacokinetics in the Preterm Population.
Abduljalil, K; Jamei, M; Johnson, TN; Pan, X; Pansari, A, 2020
)
0.56
" We present a pharmacodynamic model for moderate sedation using midazolam, alfentanil and propofol."( Pharmacodynamic modeling of moderate sedation and rationale for dosing using midazolam, propofol and alfentanil.
Chang, WK; Kuo, IT; Liou, JY; Ting, CK; Tsou, MY, 2023
)
1.36

Compound-Compound Interactions

Remimazolam benzenesulfonate combined with alfentanil can be used as a comfort anesthesia and painless anesthesia protocol in plastic surgery.

ExcerptReferenceRelevance
" Compared to vecuronium, pancuronium increased heart rate, and protected from arterial hypotension, when combined with low-dose alfentanil."( Alfentanil combined with vecuronium or pancuronium: haemodynamic implications.
Oikkonen, M, 1992
)
1.93
"The usefulness of alfentanil for eye surgery, when combined with either vecuronium or pancuronium, was evaluated in 44 fit anticholinergized patients."( Alfentanil combined with vecuronium or pancuronium for use in eye surgery.
Oikkonen, MP, 1992
)
2.06
"To investigate the pharmacokinetics of propofol in combination with epidural anesthesia or with intravenous (i."( Clinical pharmacokinetics of propofol given as a constant-rate infusion and in combination with epidural blockade.
Hartvig, P; Nilsson, A; Persson, PM; Wessén, A,
)
0.13
" In Group 1, a continuous infusion of propofol was combined with an epidural block with bupivacaine."( Clinical pharmacokinetics of propofol given as a constant-rate infusion and in combination with epidural blockade.
Hartvig, P; Nilsson, A; Persson, PM; Wessén, A,
)
0.13
" Nevertheless, the concentration-time profile changed during infusion, rendering the described infusion regimen, in combination with epidural anesthesia, unsatisfactory for adequate hypnosis."( Clinical pharmacokinetics of propofol given as a constant-rate infusion and in combination with epidural blockade.
Hartvig, P; Nilsson, A; Persson, PM; Wessén, A,
)
0.13
" This observation, combined with the known population variability in P450 3A4 activity, provides a mechanistic explanation for the interindividual variability in alfentanil disposition."( The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions.
Bowdle, A; Cox, K; Kharasch, ED; Kunze, KL; Mautz, D; Russell, M; Thummel, KE, 1997
)
0.77
" Volatile anesthetics are commonly combined with opioids."( Drug interactions: volatile anesthetics and opioids.
Gan, TJ; Ginsberg, B; Glass, PS; Howell, S, 1997
)
0.3
"Remifentanil anesthesia, combined with small-dose propofol, desflurane, or sevoflurane, enables predictably fast and smooth early recovery after ear, nose, and throat surgery."( Recovery after anesthesia with remifentanil combined with propofol, desflurane, or sevoflurane for otorhinolaryngeal surgery.
Loop, T; Priebe, HJ, 2000
)
0.31
"Our results show that although both techniques proved effective for sedation in patients undergoing fiberoptic bronchoscopy, ketamine is superior to alfentanil when used in combination with propofol because of the high patient satisfaction and amnesia."( Comparison of alfetanil and ketamine in combination with propofol for patient-controlled sedation during fiberoptic bronchoscopy.
Hwang, J; Jeon, Y; Lim, YJ; Oh, YS; Park, HP, 2005
)
0.53
" Verify its use for studying drug-drug interactions."( An in silico transwell device for the study of drug transport and drug-drug interactions.
Garmire, DG; Garmire, LX; Hunt, CA, 2007
)
0.34
" Those components were used to exemplify drug-drug interaction studies."( An in silico transwell device for the study of drug transport and drug-drug interactions.
Garmire, DG; Garmire, LX; Hunt, CA, 2007
)
0.34
"The ISTD is an example of a new class of simulation models capable of realistically representing complex drug transport and drug-drug interaction phenomena."( An in silico transwell device for the study of drug transport and drug-drug interactions.
Garmire, DG; Garmire, LX; Hunt, CA, 2007
)
0.34
" To achieve quality anesthesia and successful, fast recovery with minimal morbidity without the use of volatile anesthetic, the choice of drug combination has to be centered on one rapid- and short-acting hypnotic, opioid and non-depolarizing muscle relaxant."( The optimal pediatric induction dose of propofol in combination with reduced-dose rocuronium and alfentanil for day-case tonsillectomy in children.
Bartolek, D; Bartolek, F; Cavrić, G; Jakobović, J; Lajtman, Z; Zdravcević-Sakić, K, 2007
)
0.56
"As a novel and effective approach, response surface model is used in the study of drug-drug interactions."( [Progress in the study of response surface modeling in investigation of drug-drug interaction in anesthetic drugs].
Bi, SS; Guan, Z; Lu, W; Yang, L; Zhang, LP; Zhou, TY, 2008
)
0.35
" This study evaluated the sedative efficacy of intranasal dexmedetomidine in combination with patient-controlled sedation (PCS) for upper gastrointestinal endoscopy."( Intranasal dexmedetomidine in combination with patient-controlled sedation during upper gastrointestinal endoscopy: a randomised trial.
Cheung, CW; Chu, KM; Irwin, MG; Liu, J; Qiu, Q, 2015
)
0.42
" Deep sedation by intravenous propofol combined with an opioid has recently become the preferred sedation technique."( Sedation with propofol during ERCP: is the combination with esketamine more effective and safer than with alfentanil? Study protocol for a randomized controlled trial.
de Jong, E; Eberl, S; Hollmann, MW; Koers, L; Preckel, B; Schneider, T; van Hooft, JE, 2017
)
0.67
" Statistically significant differences were observed for remifentanil in comparison to fentanyl when combined with propofol: Propofol dose (in mg) -76."( Comparison of Fentanyl, Remifentanil, Sufentanil and Alfentanil in Combination with Propofol for General Anesthesia: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Sivaramakrishnan, G; Sridharan, K, 2019
)
0.76
"To conclude, we found that remifentanil has a statistically significant anesthetic profile than fentanyl when combined with propofol."( Comparison of Fentanyl, Remifentanil, Sufentanil and Alfentanil in Combination with Propofol for General Anesthesia: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Sivaramakrishnan, G; Sridharan, K, 2019
)
0.76
" Our study was to evaluate the effects of different doses of remimazolam combined with alfentanil in colonoscopic polypectomy."( Sedative effect of remimazolam combined with alfentanil in colonoscopic polypectomy: a prospective, randomized, controlled clinical trial.
Chu, T; Wang, J; Xin, Y; Xu, A, 2022
)
1.2
"Remimazolam combined with alfentanil have a non-inferior sedative effect than propofol during the colonoscopic polypectomy."( Sedative effect of remimazolam combined with alfentanil in colonoscopic polypectomy: a prospective, randomized, controlled clinical trial.
Chu, T; Wang, J; Xin, Y; Xu, A, 2022
)
1.28
"Propofol can be used alone or in combination with opioids during gastroscopy."( A comparative study on the efficacy and safety of propofol combined with different doses of alfentanil in gastroscopy: a randomized controlled trial.
Guan, ZY; Wang, CM; Wang, LL; Zhang, J; Zhang, YW; Zhao, P, 2023
)
1.13
"5 mg/kg propofol combined with 3 μg/kg alfentanil is more suitable for patients undergoing gastroscopy, and the dose of alfentanil can be reduced according to the patient's actual physical condition."( A comparative study on the efficacy and safety of propofol combined with different doses of alfentanil in gastroscopy: a randomized controlled trial.
Guan, ZY; Wang, CM; Wang, LL; Zhang, J; Zhang, YW; Zhao, P, 2023
)
1.4
"This study aims to observe the safety and effectiveness of remimazolam benzenesulfonate combined with alfentanil for painless and comfort anesthesia in plastic surgery."( Use of Remimazolam Combined With Alfentanil for Plastic Surgery Anesthesia Cases: A Clinical Trial.
Huang, Y; Sun, H; Tan, X; Xu, K, 2023
)
1.41
"Remimazolam benzenesulfonate combined with alfentanil can be used as a comfort anesthesia and painless anesthesia protocol in plastic surgery, which has the advantages of rapid onset of action, safety and comfort for patients, rapid recovery, and good cooperation."( Use of Remimazolam Combined With Alfentanil for Plastic Surgery Anesthesia Cases: A Clinical Trial.
Huang, Y; Sun, H; Tan, X; Xu, K, 2023
)
1.45
" The objective of this study was to compare the safety and efficacy profiles of the remimazolam and propofol when combined with alfentanil for sedation during ERCP procedures."( A randomized, controlled clinical trial comparing remimazolam to propofol when combined with alfentanil for sedation during ERCP procedures.
Chen, HR; Dong, SA; Guo, Y; Li, HX; Li, WZ; Liu, SS; Song, K; Wang, JH; Wu, LL; Wu, LN; Yu, JB; Zhang, L, 2023
)
1.34
"During elective ERCP, patients administered with remimazolam showed fewer respiratory depression events under deep sedation with hemodynamic advantages over propofol when administered in combination with alfentanil."( A randomized, controlled clinical trial comparing remimazolam to propofol when combined with alfentanil for sedation during ERCP procedures.
Chen, HR; Dong, SA; Guo, Y; Li, HX; Li, WZ; Liu, SS; Song, K; Wang, JH; Wu, LL; Wu, LN; Yu, JB; Zhang, L, 2023
)
1.32
"To observe the effect of low-dose propofol combined with dexamethasone on the prevention of postoperative nausea and vomiting (PONV) in gynaecological day surgery under remimazolam-based general anesthesia."( Effect of low-dose propofol combined with dexamethasone on the prevention of postoperative nausea and vomiting in gynaecological day surgery under remimazolam-based general anesthesia.
Ji, F; Liu, M; Man, Y; Wei, Y; Xiao, H, 2023
)
0.91
"The effect of low-dose propofol combined with dexamethasone to prevent PONV under remimazolam-based general anesthesia was similar to that of droperidol combined with dexamethasone, both of which significantly reduced the incidence of PONV in the PACU compared to dexamethasone alone."( Effect of low-dose propofol combined with dexamethasone on the prevention of postoperative nausea and vomiting in gynaecological day surgery under remimazolam-based general anesthesia.
Ji, F; Liu, M; Man, Y; Wei, Y; Xiao, H, 2023
)
0.91
" The aim of this study was to investigate the effects of remimazolam besylate combined with alfentanil in patients undergoing fiberoptic bronchoscopy with preserved spontaneous breathing."( Effectiveness of remimazolam besylate combined with alfentanil for fiberoptic bronchoscopy with preserved spontaneous breathing: a prospective, randomized, controlled clinical trial.
Chen, ZJ; Li, JY; Wang, JF; Xu, L; Yu, L; Zhang, L, 2023
)
1.38
"Remimazolam besylate combined with alfentanil for painless fiberoptic bronchoscopy can better preserve the patient's spontaneous breathing and reduce the incidence of respiratory depression during the inspection than propofol."( Effectiveness of remimazolam besylate combined with alfentanil for fiberoptic bronchoscopy with preserved spontaneous breathing: a prospective, randomized, controlled clinical trial.
Chen, ZJ; Li, JY; Wang, JF; Xu, L; Yu, L; Zhang, L, 2023
)
1.44
" The purpose of this study was to investigate the anesthetic effect of different doses of alfentanil combined with ciprofol in elderly patients undergoing endoscopic retrograde cholangiopancreatography (ERCP)."( Comparison of anesthetic effects of different doses of alfentanil combined with ciprofol in elderly patients undergoing ERCP: a randomized controlled trial.
Gu, X; Hu, J; Ji, F; Liu, N; Luo, Y; Zhu, W; Zhu, X, 2023
)
1.38
"25μg/kg/min combined with ciprofol were low, and the anesthetic effect was the best."( Comparison of anesthetic effects of different doses of alfentanil combined with ciprofol in elderly patients undergoing ERCP: a randomized controlled trial.
Gu, X; Hu, J; Ji, F; Liu, N; Luo, Y; Zhu, W; Zhu, X, 2023
)
1.16

Bioavailability

ExcerptReferenceRelevance
" The calculated bioavailability after intranasal administration was 64."( Pharmacokinetics of intranasal alfentanil.
Boerger, N; Meissner, W; Schwagmeier, R; Striebel, HW, 1995
)
0.58
" This investigation characterized the bioavailability and first-pass metabolism of oral ALF and tested the hypotheses that (1) first-pass ALF clearance reflects first-pass CYP3A activity, (2) miosis after oral ALF will reflect intestinal and hepatic CYP3A activity, and (3) miosis can approximate plasma concentration-based pharmacokinetic measures for IV and oral ALF as a noninvasive in vivo probe for hepatic and first-pass CYP3A activity and drug interactions."( Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
Hoffer, C; Kharasch, ED; Sheffels, P; Walker, A, 2004
)
0.64
"51 to 0); and increased bioavailability (from 37 to 95%)."( Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities.
Bedynek, PS; Hoffer, C; Kharasch, ED; Walker, A; Whittington, D, 2008
)
0.35
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36

Dosage Studied

The aim of this study was to characterize within-patient alfentanil dose-response curves for the relief of spontaneous postoperative pain. A placebo-controlled, double-blind study was conducted in 60 patients to determine dose- response and effects on my.

ExcerptRelevanceReference
" Quantal dose-response curves were determined in 400 female patients for the drugs individually and in combination."( Hypnotic and anaesthetic interactions between midazolam, propofol and alfentanil.
Chui, PT; Plummer, JL; Short, TG, 1992
)
0.52
" For each effect, data were converted into quantal responses and were then transformed to probit-log dose-response curves for analysis."( Elucidation of dose-effect relationships for different opiate effects using alfentanil in the spontaneously ventilating rat.
Negus, SS; Weinger, MB; Yang, PK, 1992
)
0.51
"The effect of midazolam on the induction dose-response curve for alfentanil was studied in non-premedicated ASA physical status I or II patients."( Sedation in the ICU.
Kissin, I; Vinik, HR, 1991
)
0.52
" During a 60 minutes period the patients were first anaesthesized with an ED50 and then titrated to a dosage correlating with an ED95."( [O2 uptake and CO2 production during total intravenous propofol-alfentanil anesthesia under steady-state conditions. Is O2 uptake a parameter for assessing the depth of anesthesia?].
Hausmann, D; Krajewski, W; Schüttler, J; Stoeckel, H, 1991
)
0.52
" An examination of the descending limb of the dose-response functions revealed that lowered response rates for cocaine and ketamine were correlated with increases in run time and small and inconsistent effects on postreinforcement pause time."( Analysis of fixed-ratio behavior maintained by drug reinforcers.
Skjoldager, P; Winger, G; Woods, JH, 1991
)
0.28
"In an attempt to maintain stable levels of an alpha 2-adrenergic agonist throughout the perioperative period, two different oral-transdermal clonidine dosage regimens were administered according to a randomized, double-blind, placebo-controlled study in patients undergoing abdominal surgery."( Clinical efficacy of oral-transdermal clonidine combinations during the perioperative period.
Duncan, SR; Jarvis, DJ; Maze, M; Segal, IS; White, PF, 1991
)
0.28
"Three different dosage schemes of propofol infusions combined with a fixed-rate alfentanil infusion were investigated in total intravenous anaesthesia."( Total intravenous anaesthesia with propofol, alfentanil, and oxygen-air: three different dosage schemes.
Deen, L; Helmers, HJ; van Leeuwen, L; Zuurmond, WW, 1990
)
0.77
" A lower dosage of each substance is necessary to maintain a better state of analgosedation."( [Analgesia and sedation in neurosurgical intensive care patients].
Brandt, L; el Gindi, M; Hundt, F, 1990
)
0.28
" A placebo-controlled, double-blind study was conducted in 60 patients to determine dose-response and effects on myocardial performance of alfentanil when used to attenuate this cardiovascular response."( Alfentanil controls the haemodynamic response during rapid-sequence induction of anaesthesia.
Hull, KA; Martineau, RJ; Miller, DR; Tousignant, CP, 1990
)
1.92
" A dose-response relationship was evident for the antiemetic effect of droperidol."( Intravenous droperidol decreases nausea and vomiting after alfentanil anesthesia without increasing recovery time.
Coyle, JP; Jorgensen, NH,
)
0.37
"Alfentanil, a short-acting congener of fentanyl, was studied as an analgesic sedative in monitored anesthetic care for outpatient cataract surgery with the intent of investigating efficacy in this setting and establishing dosage guidelines."( Monitored anesthetic care for outpatient cataract surgery with alfentanil.
Griffis, CA, 1990
)
1.96
"The effects of alfentanil on the midazolam dose-response curve for hypnosis was studied with response to the verbal command as an end point in 95 patients."( Alfentanil potentiates midazolam-induced unconsciousness in subanalgesic doses.
Bradley, EL; Castillo, R; Kissin, I; Vinik, HR, 1990
)
2.07
" The patient's cardiac insufficiency and chronic bronchitis made a balanced anesthesia with reduced dosage of rapifen and halothane necessary."( [Difficult intubation and anesthesia in Pfaundler-Hurler disease].
Falk, K; Gross, H; Zinganell, K, 1989
)
0.28
"The effect of midazolam on the induction dose-response curve for alfentanil was studied in nonpremedicated ASA physical status I or II patients."( Midazolam-alfentanil synergism for anesthetic induction in patients.
Bradley, EL; Kissin, I; Vinik, HR, 1989
)
0.92
" When the C1 antibody was combined with an iodinated analog to fentanyl, good detectability of alpha-methylfentanyl and 3-methylfentanyl, in terms of fentanyl equivalents, was obtained from urine samples of dosed mares."( Pharmacologic effects and detection methods of methylated analogs of fentanyl in horses.
Blake, JW; Tai, CL; Tai, HH; Tobin, T; Weckman, TJ; Woods, WE, 1989
)
0.28
" The opioid antagonist, quadazocine, produced dose-dependent, parallel shifts to the right in the alfentanil dose-response curve."( Reinforcing effect of alfentanil is mediated by mu opioid receptors: apparent pA2 analysis.
Bertalmio, AJ; Woods, JH, 1989
)
0.81
" The slopes of the monotonic dose-response curves for the five opioids did not differ significantly."( Studies of the pharmacology and pathology of intrathecally administered 4-anilinopiperidine analogues and morphine in the rat and cat.
Durant, PA; Noueihed, RY; Yaksh, TL, 1986
)
0.27
" After SUF dosing in dogs, N-[4-(methoxymethyl)-4-piperidinyl]-N-phenylpropanamide was more abundant than M5."( Excretion and biotransformation of alfentanil and sufentanil in rats and dogs.
Hendrickx, J; Heykants, J; Hurkmans, R; Lauwers, W; Meuldermans, W; Swysen, E; Thijssen, J; Timmerman, P; Woestenborghs, R,
)
0.41
"Alfentanil in low dosage (8 micrograms kg-1) as an analgesic agent for short duration surgery was evaluated."( Alfentanil for short duration laparoscopic procedures.
Lee, KS; Purcell, GJ; Rae, BR; White, B, 1986
)
3.16
"Five different dosage schemes for alfentanil administration supplemented with thiopentone, pancuronium and N2O/O2 have been studied in 25 patients undergoing elective cholecystectomy."( Alfentanil anaesthesia in gall-bladder surgery.
Hole, A; Raeder, JC, 1986
)
1.99
" The pharmacokinetic and pharmacodynamic components of each patient's dose-response relationship were evaluated simultaneously."( Decreased fentanyl and alfentanil dose requirements with age. A simultaneous pharmacokinetic and pharmacodynamic evaluation.
Scott, JC; Stanski, DR, 1987
)
0.58
" Using these population pharmacokinetic parameters, one can predict (estimate) the plasma concentration time course of alfentanil for any given dosage scheme."( Evaluating the accuracy of using population pharmacokinetic data to predict plasma concentrations of alfentanil.
Ausems, ME; Maitre, PO; Stanski, DR; Vozeh, S, 1988
)
0.7
"Three different dosage regimens of alfentanil were compared with boluses of fentanyl in 80 patients who underwent a variety of surgical procedures."( Alfentanil infusions. Comparison of bolus administration of fentanyl with three alfentanil infusion regimens.
Sleigh, JW; Stuart-Taylor, ME, 1987
)
1.99
" The empirical method of adjusting dosage to clinical response, as currently applied to inhalational anaesthesia, proved to be a useful experimental method of defining dosage schemes before adequate knowledge of the pharmacodynamic and pharmacokinetic variables of alfentanil was available."( The development of alfentanil infusions for cardiac anaesthesia.
de Lange, S, 1987
)
0.78
" The following dosage scheme is proposed: a loading dose of 100 micrograms kg-1, given either in one or two doses, or as a fast infusion administered over 10 min, followed by a maintenance infusion at a rate of 1 microgram kg-1 min-1."( Practical aspects of alfentanil infusion.
Geerts, P; Heykants, J; Noorduin, H; Vanden Bussche, G, 1987
)
0.59
" We conclude that: (1) a more flexible dosage schedule is required in order to prevent disturbing movement of the patient during the procedure and (2) patients who received alfentanil were not street-worthy earlier than those who were given fentanyl."( Double blind comparison of alfentanil N2O and fentanyl N2O for outpatient surgical procedures.
Enright, AB; Parker, JB, 1988
)
0.77
" For most patients, using population pharmacokinetic parameters of alfentanil for dosing regimen allows accurate prediction of the plasma concentration of the drug over time."( Bayesian forecasting improves the prediction of intraoperative plasma concentrations of alfentanil.
Maitre, PO; Stanski, DR, 1988
)
0.73
" The dosage of alfentanil required was comparable in both Asian and European patients, but recovery was slower in the Asian patients."( A comparison of alfentanil requirements in European and Asian patients during general anaesthesia.
Aun, C; Carley, RH; Chan, K; Houghton, IT; Lams, YM; Salmon, NP; Thornton, JA, 1988
)
0.97
"Alfentanil in combination with etomidate and N2O/O2 was given to 50 patients as single dosage (0."( [Alfentanil in routine clinical use. A study of 50 patients].
Löffler, B, 1985
)
2.62
" The dosage of etomidate and methohexitone was lowe than that reported in the literature."( [Etomidate versus methohexital for intravenous anesthesia with alfentanyl and nitrous oxide-oxygen. A double-blind study of circulatory behavior and postoperative course].
Papst-Baierl, D; Sold, M; Weis, KH, 1985
)
0.27
" bolus dose of 50 micrograms kg-1 alfentanil were studied during surgical anaesthesia in 10 elderly patients and compared with those of the same dosage in nine young adults."( Alfentanil used in the aged: a clinical comparison with its use in young patients.
Helmers, JH; Noorduin, H; van Leeuwen, L, 1985
)
1.99
" Examination of the effect on expired CO2 concentration at 4 minutes reveals a highly significant dose-response relationship with the three doses of Alfentanyl."( Human volunteer studies of Alfentanyl (R39209), a new short-acting narcotic analgesic.
Kay, B; Pleuvry, B, 1980
)
0.26
" Alfentanil dosage should therefore be reduced in elderly patients when large single doses, multiple doses, or long-term infusions are required."( Alfentanil kinetics in the elderly.
Helmers, H; Heykants, J; Noorduin, H; Van Peer, A; Woestenborghs, R, 1984
)
2.62
"In this study we attempted to define the minimal dosage of alfentanil (AF) needed in combination with nitrous oxide to provide satisfactory anesthetic conditions for lower abdominal gynecologic surgery."( Variable rate infusion of alfentanil as a supplement to nitrous oxide anesthesia for general surgery.
Ausems, ME; de Lange, S; Hug, CC, 1983
)
0.81
" The purpose of this study was to model the pharmacokinetics of alfentanil in children undergoing cardiac surgery to provide accurate dosage titration intraoperatively as well as in the postoperative period."( Pharmacokinetics of computer-controlled alfentanil administration in children undergoing cardiac surgery.
Brand, SC; Engstrom, R; Fiset, P; Fitzgerald, D; Hsu, F; Mathers, L; Shafer, SL, 1995
)
0.8
" An individual dose-response curve of the atracurium-vecuronium combination was determined for every patient and its potency compared with that of the parent agents alone."( Synergism between atracurium and vecuronium in infants and children during nitrous oxide-oxygen-alfentanil anaesthesia.
Jalkanen, L; Meretoja, OA; Taivainen, T; Wirtavuori, K, 1994
)
0.51
" It was the aim of our study to investigate the onset of action, the intubation conditions and the course of relaxation using two different dosage regimes."( [Mechanomyographic and electromyographic studies of endotracheal intubation with 2 different rocuronium dosages].
Benad, G; Hofmockel, R; Kabott, A, 1994
)
0.29
"We determined the possible benefits of a new opioid, trefentanil, relative to fentanyl and alfentanil using high-resolution pharmacokinetic-pharmacodynamic modeling and computer simulations of clinical dosing scenarios."( Pharmacokinetic-pharmacodynamic modeling in drug development: application to the investigational opioid trefentanil.
Dyck, JB; Lemmens, HJ; Shafer, SL; Stanski, DR, 1994
)
0.51
" Finally, we used computer simulations to predict offset of opioid effects of trefentanil, fentanyl, and alfentanil when given in different dosing schemes."( Pharmacokinetic-pharmacodynamic modeling in drug development: application to the investigational opioid trefentanil.
Dyck, JB; Lemmens, HJ; Shafer, SL; Stanski, DR, 1994
)
0.5
"We suggest that high-resolution pharmacokinetic-pharmacodynamic studies and computer simulations of clinical dosing scenarios may have significant usefulness in appreciating differences between new and established drugs in early phase I studies."( Pharmacokinetic-pharmacodynamic modeling in drug development: application to the investigational opioid trefentanil.
Dyck, JB; Lemmens, HJ; Shafer, SL; Stanski, DR, 1994
)
0.29
"86 micrograms ml-1) or induction of anaesthesia a cumulative dose-response curve of vecuronium was established to achieve a 95% depression of the twitch response."( The effect of epidural bupivacaine on vecuronium-induced neuromuscular blockade in children.
Meretoja, OA; Rosenberg, PH; Taivainen, T, 1994
)
0.29
" The HP dose-response curve for IT alfentanil delivered in liposomes was shifted slightly to the right, as compared to saline vehicle, but liposome encapsulation totally abolished the side effects that were otherwise observed at the highest IT alfentanil dose."( Antinociception and side effects of liposome-encapsulated alfentanil after spinal delivery in rats.
Ho, RJ; Shen, DD; Wallace, MS; Yaksh, TL; Yanez, AM, 1994
)
0.81
" We investigated the role of each of these primary pharmacokinetic parameters to determine values of each that would contribute to rapid recovery after various dosing schemes."( Pharmacokinetic parameters relevant to recovery from opioids.
Shafer, SL; Youngs, EJ, 1994
)
0.29
"With the dosage regimen used in this study, an initial epidural bolus with continuous infusion technique generates a steady state plasma concentration of alfentanil that is below levels associated with direct respiratory depression."( Plasma concentration profile of epidural alfentanil. Bolus followed by continuous infusion technique in the parturient: effect of epidural alfentanil and fentanyl on fetal heart rate.
Blass, NH; Christmas, JT; Moore, CH; Wilhite, AO,
)
0.6
" produced an acute rightward shift of the dose-response curves of the selective mu opioid agonists alfentanil and morphine at all tested temperatures."( In vivo determination of mu opioid receptor turnover in rhesus monkeys after irreversible blockade with clocinnamox.
Butelman, ER; Lewis, JW; Walker, EA; Woods, JH; Zernig, G, 1994
)
0.51
" One alternative is the combination of glycopyrrolate, alfentanil and suxamethonium described here, although the ideal medication and dosage still remain to be defined."( Physiological changes, plasma beta-endorphin and cortisol responses to tracheal intubation in neonates.
Koivisto, M; Pokela, ML, 1994
)
0.54
" Dose-response curves for the three drugs given separately and in combination were determined with a probit procedure and the ED50 values were compared with an isobolographic analysis."( Triple anesthetic combination: propofol-midazolam-alfentanil.
Bradley, EL; Kissin, I; Vinik, HR, 1994
)
0.54
" No difference in intubation scores or number of intubation attempts among the three dosage groups were found."( Intubating conditions and neuromuscular effects of mivacurium during propofol-alfentanil anaesthesia.
Crul, JF; Ory, JP; Van Aken, H; Vandermeersch, E; Vertommen, JD, 1995
)
0.52
" A cumulative log-probit dose-response curve of vecuronium was established."( The neuromuscular blocking effects of vecuronium during sevoflurane, halothane and balanced anaesthesia in children.
Meretoja, OA; Taivainen, T, 1995
)
0.29
" Using the cumulative dose-response technique and electromyography, we determined ED50 and ED90 of doxacurium during halothane (n = 9), isoflurane (n = 12) or alfentanil (n = 9) based anaesthesia in children aged 2-10 years."( Doxacurium pharmacodynamics in children during volatile and opioid-based anaesthesia.
Kern, C; Pittet, JF; Rouge, JC; Tassonyi, E; Wilder-Smith, OH, 1996
)
0.49
"The aim of this study was to characterize within-patient alfentanil dose-response curves for the relief of spontaneous postoperative pain and to test the closeness of relationships 1) between pain intensity and alfentanil analgesic requirements, and 2) between alfentanil requirements for analgesic and nonanalgesic (sedative and miotic) effects."( Alfentanil dose-response relationships for relief of postoperative pain.
Dashkovsky, I; Kissin, I; Oren, M; Tverskoy, M, 1996
)
1.98
"The purpose of this study was to determine the dose-response relationships for edrophonium antagonism of mivacurium-induced neuromuscular block."( Dose-response relationships for edrophonium antagonism of mivacurium-induced neuromuscular block during N2O-enflurane-alfentanil anaesthesia.
Drolet, P; Girard, M; Marcotte, J; Perreault, L, 1995
)
0.5
" For future long-term sedation and analgesia of ICU patients with propofol/alfentanil, this altered pharmacokinetic behaviour should be taken into consideration to allow a more individualized and safer dosing of this drug combination."( Pharmacokinetics and pharmacodynamics of propofol/alfentanil infusions for sedation in ICU patients.
Frenkel, C; Heye, H; Ihmsen, H; Rommelsheim, K; Schuttler, J, 1995
)
0.77
" Neuromuscular function was recorded by adductor pollicis emg and a cumulative log-probit dose-response curve of rocuronium was established."( Rocuronium in infants, children and adults during balanced anaesthesia.
Erkola, O; Juvakoski, M; Meretoja, OA; Rautoma, P; Taivainen, T, 1996
)
0.29
" Anesthetic requirements, circulatory variables, interventions, and isoproterenol dose-response curves (pre- and postoperatively) were determined."( Clonidine for major vascular surgery in hypertensive patients: a double-blind, controlled, randomized study.
Bayon, MC; Boucaud, C; Bouilloc, X; Brudon, JR; Butin, E; Danays, T; Frehring, B; Ghignone, M; Levron, JC; Petit, P; Quintin, L; Tassan, H; Tissot, S; Viale, JP, 1996
)
0.29
" The technique used and the dosage of drugs, introduced by infusion, are described."( [Propofol (Diprivan) in emergency anesthesia].
Aluan, K; Badeva, B; Bochev, D; Giurova, Z; Petrov, P; Vankov, I, 1996
)
0.29
" However, excessive dosage of these drugs may result in hazardous respiratory depression in this patient population."( Propofol and alfentanil for sedation during placement of retrobulbar block for cataract surgery.
Burns, TA; Crandall, AS; Mann, JM; Yee, JB, 1996
)
0.66
" At 1 mg/kg, CCAM caused a 300-fold shift of the alfentanil dose-response curve and also depressed the maximum response rates."( Clocinnamox inhibits the intravenous self-administration of opioid agonists in rhesus monkeys: comparison with effects on opioid agonist-mediated antinociception.
Lewis, JW; Woods, JH; Zernig, G, 1997
)
0.55
" If other P450 3A4 substrates are comparable, then menstrual cycle variability in their metabolism may not be a consideration in dosing or in the design of pharmacokinetic investigations."( Assessment of cytochrome P450 3A4 activity during the menstrual cycle using alfentanil as a noninvasive probe.
Bowdle, TA; Cox, K; Garton, K; Kharasch, ED; Lentz, G; Russell, M, 1997
)
0.53
" Through an understanding of the pharmacodynamic interaction of volatile anesthetics with opioids and the pharmacokinetic processes responsible for the recovery from drug effect, optimal dosing schemes can thus be developed."( Drug interactions: volatile anesthetics and opioids.
Gan, TJ; Ginsberg, B; Glass, PS; Howell, S, 1997
)
0.3
" Our study indicates that if appropriate dosing of propofol and alfentanil are adhered to, and proper action is taken in case of haemodynamic alterations suggestive of inadequate anaesthesia, the incidence of conscious awareness in non-cardiac TIVA with neuromuscular blockade is low."( Incidence of awareness in total i.v. anaesthesia based on propofol, alfentanil and neuromuscular blockade.
Engström, AM; Nordström, O; Persson, S; Sandin, R, 1997
)
0.77
" When changes in physiologic condition were simulated, effects on the pharmacokinetics of the opioids with possible implications for dosing were obtained only if cardiac output was varied over a wide range."( Application of physiologic models to predict the influence of changes in body composition and blood flows on the pharmacokinetics of fentanyl and alfentanil in patients.
Björkman, S; Stanski, DR; Wada, DR, 1998
)
0.5
"To estimate the optimum dosing regimen and delivery system for remifentanil, a new opioid, using computer simulations based on information from pharmacokinetic and pharmacodynamic models available for fentanyl, alfentanil and remifentanil, as well as from clinical trials of fentanyl and alfentanil."( [Characterization of dose profile of remifentanil with computer simulation: comparative study with fentanyl and alfentanyl].
Gambús, PL; Minto, CF; Schnider, TW, 1998
)
0.49
" Dosing guidelines for remifentanil, fentanyl and alfentanil were estimated for three methods of administration (bolus, bolus + variable continuous infusion or constant continuous infusion)."( [Characterization of dose profile of remifentanil with computer simulation: comparative study with fentanyl and alfentanyl].
Gambús, PL; Minto, CF; Schnider, TW, 1998
)
0.55
" The results are fairly consistent with clinical evidence, demonstrating the power of pharmacokinetic and pharmacodynamic models for rationally establishing opioid dosing guidelines."( [Characterization of dose profile of remifentanil with computer simulation: comparative study with fentanyl and alfentanyl].
Gambús, PL; Minto, CF; Schnider, TW, 1998
)
0.3
"Patient-controlled sedation (PCS) enables titration of dosage to an individual's requirements and is potentially useful in colonoscopy."( Patient-controlled sedation and analgesia, using propofol and alfentanil, during colonoscopy: a prospective randomized controlled trial.
Criswell, J; Jones, C; Kimble, J; Patel, P; Roseveare, C; Seavell, C; Shepherd, H, 1998
)
0.54
" Afterwards, the opioids were administered continuously with cumulative dosage up to total absence of motor evoked response."( Influence of fentanyl, alfentanil, and sufentanil on motor evoked potentials.
Hanisch, M; Hoeft, A; Juntke, R; Nadstawek, J; Pechstein, U; Scheufler, KM; Thees, C; Zentner, J, 1999
)
0.61
" Nonetheless, our data show that the postoperative requirement for these rapidly acting drugs is qualitatively similar to that for other opioids in that dosage escalation does not occur."( Lack of rapid development of opioid tolerance during alfentanil and remifentanil infusions for postoperative pain.
Checketts, MR; Kenny, GN; Schraag, S, 1999
)
0.55
" In the REM groups, the dosage of PRO (75 microg."( Recovery after anesthesia with remifentanil combined with propofol, desflurane, or sevoflurane for otorhinolaryngeal surgery.
Loop, T; Priebe, HJ, 2000
)
0.31
"A rigorous study of the dose-response relation of rapacuronium has, to our knowledge, yet to be performed."( Dose-response and onset/offset characteristics of rapacuronium.
Flores, F; Ghori, K; Klewicka, MM; Kopman, AF; Neuman, GG, 2000
)
0.31
" There is a complex dose-response relationship."( Alfentanil-induced epileptiform activity: a simultaneous surface and depth electroencephalographic study in complex partial epilepsy.
Barlow, MK; Cosgrove, GR; Houghton, KJ; Kearse, LA; Ross, J, 2001
)
1.75
"63 microg x kg(-1) caused a reduction in the overall concentration and dose of propofol required to produce loss of consciousness, but no significant shift in the dose-response curve compared with other studies."( The effect of intravenous dexmedetomidine premedication on the dose requirement of propofol to induce loss of consciousness in patients receiving alfentanil.
Cloote, AH; Peden, CJ; Prys-Roberts, C; Stratford, N, 2001
)
0.51
" The effects of combining alfentanil and sevoflurane on hypoxic Vi and HR responses and BIS could be predicted from the separate dose-response curves."( Response surface modeling of alfentanil-sevoflurane interaction on cardiorespiratory control and bispectral index.
Dahan, A; Nieuwenhuijs, D; Olofsen, E; Romberg, R; Sarton, E; Teppema, L, 2001
)
0.9
" The muscle relaxants were administered using bolus dosing in all groups but in the succinylcholine group."( Does monitoring of post-tetanic count prevent alarms of airway pressure or visible muscle activity during intratracheal jet ventilation? A prospective study with five different neuromuscular blocking agents.
Baer, GA; Laippala, P; Puura, AI; Rorarius, MG, 2000
)
0.31
" Modified cassette, or "cocktail," dosing is useful for assessing drug interactions in humans."( Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil.
Feldman, J; Ibrahim, AE; Karim, A; Kharasch, ED, 2003
)
0.51
" It is currently debated if the steep ascending part of the biphasic dose-response curve typically obtained in multiple-dosing lever-press-based operant conditioning procedures represents a satiety-driven, all-or-none response or if the response is gradual and tightly adjusted to the various doses of the reinforcer."( Opioids, cocaine, and food change runtime distribution in a rat runway procedure.
Saria, A; Sturm, K; Wakonigg, G; Zernig, G, 2003
)
0.32
" This gives the freedom and need to select the appropriate dosing ratio of alfentanil and propofol by other considerations."( Testing and modelling the interaction of alfentanil and propofol on the EEG.
Albrecht, S; Fechner, J; Hering, W; Ihmsen, H; Schüttler, J; Schwilden, H, 2003
)
0.82
" A dosing regimen was identified in which fexofenadine disposition was not affected by alfentanil."( Evaluation of first-pass cytochrome P4503A (CYP3A) and P-glycoprotein activities using alfentanil and fexofenadine in combination.
Hoffer, C; Kharasch, ED; Sheffels, P; Walker, A, 2005
)
0.77
"Because the rates at which therapeutics are cleared from the body can affect their effectiveness, knowing and accounting for the variables that contribute to drug clearance is of utmost importance when designing a drug dosage regimen for patients."( CYP3A probes can quantitatively predict the in vivo kinetics of other CYP3A substrates and can accurately assess CYP3A induction and inhibition.
Kharasch, ED; Thummel, KE; Watkins, PB, 2005
)
0.33
"Correct dosing of drugs in neonates, infants and children is hampered by a general lack of knowledge about drug disposition in this population."( Prediction of cytochrome p450-mediated hepatic drug clearance in neonates, infants and children : how accurate are available scaling methods?
Björkman, S, 2006
)
0.33
"The authors' controller has a similar set-point precision as previous hypnotic controllers and provides adequate alfentanil dosing during surgery."( Closed-loop control of mean arterial blood pressure during surgery with alfentanil: clinical evaluation of a novel model-based predictive controller.
Bieniok, C; Gentilini, A; Leibundgut, D; Luginbühl, M; Schnider, TW; Wymann, R, 2006
)
0.78
" They were randomly assigned to five dosage groups: placebo or 5, 10, 15, or 20 microg/kg."( Alfentanil dosage when inserting the classic laryngeal mask airway.
Critchley, LA; Gin, T; Lee, A; Yu, AL, 2006
)
1.78
" This suggests differential dose-response relationships of opioid analgesia on the sensory and affective components of pain."( Differential opioid action on sensory and affective cerebral pain processing.
Geisslinger, G; Hummel, T; Lanfermann, H; Lötsch, J; Oertel, BG; Preibisch, C; Wallenhorst, T, 2008
)
0.35
"), dose-dependently produced rightward shifts of the dose-response curve of Ro 64-6198-induced antinociception."( Behavioral effects of a synthetic agonist selective for nociceptin/orphanin FQ peptide receptors in monkeys.
Fantegrossi, WE; Galuska, CM; Ko, MC; Prinssen, EP; Wichmann, J; Woods, JH, 2009
)
0.35
"Transcutaneous PCO(2 )(PtcCO(2)), oxygen saturation, patients' tolerance, time after FB until recovery and application of drug dosage were assessed in patients receiving either midazolam with alfentanil (n = 15) or midazolam alone (n = 15) for sedation for FB."( Sedation during flexible bronchoscopy in patients with pre-existing respiratory failure: Midazolam versus Midazolam plus Alfentanil.
Dreher, M; Ekkernkamp, E; Kabitz, HJ; Storre, JH; Windisch, W, 2010
)
0.76
" This study examines whether alfentanil dosage adversely affects fertilization and/or embryo quality."( Effect of alfentanil dosage during oocyte retrieval on fertilization and embryo quality.
Bergh, C; Gejervall, AL; Lundin, K; Stener-Victorin, E, 2010
)
1.05
" Using plasma ALF concentrations and area under the curve (AUC), clearance, or single-point concentrations, both simultaneous and sequential dosing provided equivalent results and detected hepatic and intestinal CYP3A induction and inhibition."( Concurrent assessment of hepatic and intestinal cytochrome P450 3A activities using deuterated alfentanil.
Blood, J; Buck, N; Kharasch, ED; Kim, T; London, A; Mach, RH; Vangveravong, S, 2011
)
0.59
"With the dosing history from two studies in orthopaedic patients anaesthetized with propofol or inhalation anaesthetics the alfentanil plasma concentration over time was calculated with eight PK parameter sets."( Pharmacokinetic parameter sets of alfentanil revisited: optimal parameters for use in target controlled infusion and anaesthesia display systems.
Baechtold, M; Hartwich, V; Luginbühl, M; Schnider, TW; Schumacher, PM; Sigmond, N, 2013
)
0.88
"The objective was to assess the effect on stress biomarkers of supplemental opioid to a standard propofol dosing protocol for emergency department (ED) procedural sedation (PS)."( Randomized clinical trial of the effect of supplemental opioids in procedural sedation with propofol on serum catecholamines.
Gray, RO; Ho, JD; Miner, JR; Moore, JC; Patel, S; Plummer, D, 2013
)
0.39
"5 mg/kg every 3 minutes as needed, or propofol only, dosed in similar fashion without supplemental alfentanil."( Randomized clinical trial of the effect of supplemental opioids in procedural sedation with propofol on serum catecholamines.
Gray, RO; Ho, JD; Miner, JR; Moore, JC; Patel, S; Plummer, D, 2013
)
0.61
"Drug combination is frequently used in pain treatment, which can produce similar analgesia with reduced dosage and side effects."( Synergistic antinociception of propofol-alfentanil combination in mice.
Jia, N; Li, RL; Li, Y; Li, YW; Shi, XP; Wang, C; Wang, JW; Wen, AD; Wu, Y; Zhao, C, 2014
)
0.67
" In the three models, dose-response curves were established and their respective ED50 (50% effective dose) values were determined separately for each agent."( Synergistic antinociceptive interactions between fospropofol and alfentanil in mice.
Cao, S; Cui, J; Jia, N; Li, R; Li, Y; Wang, C; Wang, L; Wen, A; Wu, Y; Zhao, C, 2015
)
0.65
" The primary outcome parameter is the dosage of propofol necessary for an adequate level of sedation to tolerate the procedure (OAA/S < 4)."( A randomised controlled trial: can acupuncture reduce drug requirement during analgosedation with propofol and alfentanil for colonoscopy? A study protocol.
Eberl, S; Fockens, P; Hollmann, MW; Monteiro de Olivera, N; Preckel, B; Streitberger, K, 2015
)
0.63
"Opioids are integral part of anesthesia induction, but information on optimal dosing is limited."( Dose requirements of alfentanil to eliminate autonomic responses during rapid-sequence induction with thiopental 4 mg/kg and rocuronium 0.6 mg/kg.
Abou-Arab, MH; Heier, T; Rostrup, M, 2016
)
0.75
" The primary outcome was the dosage of propofol used."( Electroacupuncture-reduced sedative and analgesic requirements for diagnostic EUS: a prospective, randomized, double-blinded, sham-controlled study.
Chan, SKC; Chong, CCN; Lai, PBS; Lau, JYW; Leung, WW; Ng, EKW; Teoh, AYB; Tse, YK; Wu, JCY, 2018
)
0.48
" Our assumption is that a combination of propofol with esketamine reduces the dosage of individual drugs, thereby minimizing sedation side effects while keeping the same satisfaction level of patients and endoscopists."( Sedation with propofol during ERCP: is the combination with esketamine more effective and safer than with alfentanil? Study protocol for a randomized controlled trial.
de Jong, E; Eberl, S; Hollmann, MW; Koers, L; Preckel, B; Schneider, T; van Hooft, JE, 2017
)
0.67
"While the developed preterm model for the prediction of PK behaviour in preterm patients is not intended to replace clinical studies, it can potentially help with deciding on first-time dosing in this population and study design in the absence of clinical data."( Preterm Physiologically Based Pharmacokinetic Model. Part II: Applications of the Model to Predict Drug Pharmacokinetics in the Preterm Population.
Abduljalil, K; Jamei, M; Johnson, TN; Pan, X; Pansari, A, 2020
)
0.56
" The primary outcome parameter was the total dosage of propofol."( Effect of electroacupuncture on sedation requirements during colonoscopy: a prospective placebo-controlled randomised trial.
Bourne, D; Eberl, S; Fockens, P; Hollmann, MW; Monteiro de Olivera, N; Preckel, B; Streitberger, K, 2020
)
0.56
"The dosage of propofol required (median [IQR]) was not significantly different between the three groups (EA group 147 μg/kg/min [109-193] vs SA group 141 μg/kg/min [123- 180] vs PA group 141 μg/kg/min [112-182]; P=0."( Effect of electroacupuncture on sedation requirements during colonoscopy: a prospective placebo-controlled randomised trial.
Bourne, D; Eberl, S; Fockens, P; Hollmann, MW; Monteiro de Olivera, N; Preckel, B; Streitberger, K, 2020
)
0.56
"We demonstrate the accurate prediction of a three-drug response surface model for moderate sedation and simulation suggests a rational dosing strategy for moderate sedation with midazolam, alfentanil and propofol."( Pharmacodynamic modeling of moderate sedation and rationale for dosing using midazolam, propofol and alfentanil.
Chang, WK; Kuo, IT; Liou, JY; Ting, CK; Tsou, MY, 2023
)
1.32
" There was no significant difference in general data, anesthesia time, the recovery time of patients and dosage of remimazolam and alfentanil among the 3 groups (P > ."( Effect of low-dose propofol combined with dexamethasone on the prevention of postoperative nausea and vomiting in gynaecological day surgery under remimazolam-based general anesthesia.
Ji, F; Liu, M; Man, Y; Wei, Y; Xiao, H, 2023
)
1.11
" The occurrence of hypotension, bradycardia, hypoxemia and the degree of body movement were secondary outcomes, as well as the moment at which consciousness was lost, the interval between the end of anesthesia and the operating room's release of the patient, and the overall dosage of alfentanil administered during the procedure."( Cardiopulmonary Adverse Events of Remimazolam versus Propofol During Cervical Conization: A Randomized Controlled Trial.
Huang, Z; Ma, L; Mu, X; Nie, H; Wang, L; Wang, Y; Zheng, Z, 2023
)
1.09
" Adverse events(including respiratory depression, body movement and hypoxemia),the dosage of ciprofol, the time of operation time and awakening were recorded."( Comparison of anesthetic effects of different doses of alfentanil combined with ciprofol in elderly patients undergoing ERCP: a randomized controlled trial.
Gu, X; Hu, J; Ji, F; Liu, N; Luo, Y; Zhu, W; Zhu, X, 2023
)
1.16
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (5)

RoleDescription
opioid analgesicA narcotic or opioid substance, synthetic or semisynthetic agent producing profound analgesia, drowsiness, and changes in mood.
mu-opioid receptor agonistA compound that exhibits agonist activity at the mu-opioid receptor.
intravenous anaestheticnull
central nervous system depressantA loosely defined group of drugs that tend to reduce the activity of the central nervous system.
peripheral nervous system drugA drug that acts principally at one or more sites within the peripheral neuroeffector systems, the autonomic system, and motor nerve-skeletal system.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
piperidines
monocarboxylic acid amideA carboxamide derived from a monocarboxylic acid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Alfentanil Action Pathway3111

Protein Targets (6)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bile salt export pumpHomo sapiens (human)IC50 (µMol)135.00000.11007.190310.0000AID1443980
ATP-dependent translocase ABCB1Homo sapiens (human)IC50 (µMol)112.00000.00022.318510.0000AID679130
Mu-type opioid receptorRattus norvegicus (Norway rat)IC50 (µMol)0.03890.00010.887410.0000AID1576134
Mu-type opioid receptorRattus norvegicus (Norway rat)Ki0.00820.00000.38458.6000AID151590
Kappa-type opioid receptorCavia porcellus (domestic guinea pig)IC50 (µMol)10.00000.00030.71237.0700AID147961
Mu-type opioid receptorCavia porcellus (domestic guinea pig)IC50 (µMol)0.01500.00020.660310.0000AID148994
Sigma non-opioid intracellular receptor 1Cavia porcellus (domestic guinea pig)IC50 (µMol)10.00000.00202.123310.0000AID1576132
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (37)

Processvia Protein(s)Taxonomy
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
G2/M transition of mitotic cell cycleATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic metabolic processATP-dependent translocase ABCB1Homo sapiens (human)
response to xenobiotic stimulusATP-dependent translocase ABCB1Homo sapiens (human)
phospholipid translocationATP-dependent translocase ABCB1Homo sapiens (human)
terpenoid transportATP-dependent translocase ABCB1Homo sapiens (human)
regulation of response to osmotic stressATP-dependent translocase ABCB1Homo sapiens (human)
transmembrane transportATP-dependent translocase ABCB1Homo sapiens (human)
transepithelial transportATP-dependent translocase ABCB1Homo sapiens (human)
stem cell proliferationATP-dependent translocase ABCB1Homo sapiens (human)
ceramide translocationATP-dependent translocase ABCB1Homo sapiens (human)
export across plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
transport across blood-brain barrierATP-dependent translocase ABCB1Homo sapiens (human)
positive regulation of anion channel activityATP-dependent translocase ABCB1Homo sapiens (human)
carboxylic acid transmembrane transportATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic transport across blood-brain barrierATP-dependent translocase ABCB1Homo sapiens (human)
regulation of chloride transportATP-dependent translocase ABCB1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (18)

Processvia Protein(s)Taxonomy
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
protein bindingATP-dependent translocase ABCB1Homo sapiens (human)
ATP bindingATP-dependent translocase ABCB1Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
efflux transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
ATP hydrolysis activityATP-dependent translocase ABCB1Homo sapiens (human)
transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
ubiquitin protein ligase bindingATP-dependent translocase ABCB1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
carboxylic acid transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
phosphatidylcholine floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
phosphatidylethanolamine flippase activityATP-dependent translocase ABCB1Homo sapiens (human)
ceramide floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (14)

Processvia Protein(s)Taxonomy
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
cytoplasmATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
cell surfaceATP-dependent translocase ABCB1Homo sapiens (human)
membraneATP-dependent translocase ABCB1Homo sapiens (human)
apical plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
extracellular exosomeATP-dependent translocase ABCB1Homo sapiens (human)
external side of apical plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (155)

Assay IDTitleYearJournalArticle
AID179544General recovery of motor activity in minutes.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
New 1-(heterocyclylalkyl)-4-(propionanilido)-4-piperidinyl methyl ester and methylene methyl ether analgesics.
AID171767Upper limit dose for morphinomimetic activity was determined in rats by tail withdrawal reflex test (TWR),at time 1/16 hr hour after administration intravenously1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthetic 1,4-disubstituted-1,4-dihydro-5H-tetrazol-5-one derivatives of fentanyl: alfentanil (R 39209), a potent, extremely short-acting narcotic analgesic.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1443980Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch2010Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID128469Analgesic activity in a standard mouse hot plate assay, the value ranges from 0.022- 0.0681989Journal of medicinal chemistry, May, Volume: 32, Issue:5
Synthesis and pharmacological evaluation of 4,4-disubstituted piperidines.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID540219Volume of distribution at steady state in monkey after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID178189Effective dose for morphinomimetic activity was determined in rats by tail withdrawal reflex test (TWR),at time 4 hour after administration intravenously1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthetic 1,4-disubstituted-1,4-dihydro-5H-tetrazol-5-one derivatives of fentanyl: alfentanil (R 39209), a potent, extremely short-acting narcotic analgesic.
AID178187Effective dose for morphinomimetic activity was determined in rats by tail withdrawal reflex test (TWR),at time 1 hr after administration intravenously1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthetic 1,4-disubstituted-1,4-dihydro-5H-tetrazol-5-one derivatives of fentanyl: alfentanil (R 39209), a potent, extremely short-acting narcotic analgesic.
AID169445Change in heart rate of male Sprague-Dawley rats, as compared to the control, using rat tail flick after the administration of a dose of 16.01989Journal of medicinal chemistry, Dec, Volume: 32, Issue:12
4-Phenyl- and 4-heteroaryl-4-anilidopiperidines. A novel class of analgesic and anesthetic agents.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID150412In vitro affinity to displace [3H]naloxone from opiate receptor in freshly prepared rat brain homogenates1989Journal of medicinal chemistry, May, Volume: 32, Issue:5
Synthesis and pharmacological evaluation of 4,4-disubstituted piperidines.
AID196362Recovery of motor co-ordination after intravenous injection of ED100 and regaining of righting after 90 seconds later.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
New 1-(heterocyclylalkyl)-4-(propionanilido)-4-piperidinyl methyl ester and methylene methyl ether analgesics.
AID114189Analgesic activity in nonfasted male mice at 55 degree C using Hot plate assay1989Journal of medicinal chemistry, Dec, Volume: 32, Issue:12
4-Phenyl- and 4-heteroaryl-4-anilidopiperidines. A novel class of analgesic and anesthetic agents.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID148994In vitro binding activity against opioid receptor mu using [3H]DAGO) as radioligand1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
New 1-(heterocyclylalkyl)-4-(propionanilido)-4-piperidinyl methyl ester and methylene methyl ether analgesics.
AID25826Partition coefficient at 25 degree centigrades1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthetic 1,4-disubstituted-1,4-dihydro-5H-tetrazol-5-one derivatives of fentanyl: alfentanil (R 39209), a potent, extremely short-acting narcotic analgesic.
AID169452Change in mean arterial pressure of male Sprague-Dawley rats;,as compared to control, using rat hot plate1989Journal of medicinal chemistry, Dec, Volume: 32, Issue:12
4-Phenyl- and 4-heteroaryl-4-anilidopiperidines. A novel class of analgesic and anesthetic agents.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID178022Effective dose for analgesic activity in male Sprague-Dawley rats, using tail-flick method1989Journal of medicinal chemistry, Dec, Volume: 32, Issue:12
4-Phenyl- and 4-heteroaryl-4-anilidopiperidines. A novel class of analgesic and anesthetic agents.
AID496831Antimicrobial activity against Cryptosporidium parvum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID169524Lower limit dose for morphinomimetic activity was determined in rats by tail withdrawal reflex test (TWR),at time 1/8 hr hour after administration intravenously1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthetic 1,4-disubstituted-1,4-dihydro-5H-tetrazol-5-one derivatives of fentanyl: alfentanil (R 39209), a potent, extremely short-acting narcotic analgesic.
AID174633Duration to produce analgesic activity was measured in rats by tail withdrawal reflex test (TWR), administered by intravenous at peak time 1 min (16 X MED50 dose)1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthetic 1,4-disubstituted-1,4-dihydro-5H-tetrazol-5-one derivatives of fentanyl: alfentanil (R 39209), a potent, extremely short-acting narcotic analgesic.
AID196361Recovery of motor co-ordination after intravenous injection of ED100 and regaining of righting after 180 seconds later.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
New 1-(heterocyclylalkyl)-4-(propionanilido)-4-piperidinyl methyl ester and methylene methyl ether analgesics.
AID127629Duration of analgesic effect using mouse hot plate assay1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Synthesis and pharmacological evaluation of a series of new 3-methyl-1,4-disubstituted-piperidine analgesics.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID169410Lower limit dose for morphinomimetic activity was determined in rats by tail withdrawal reflex test (TWR),at time 1/2 hour after administration intravenously1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthetic 1,4-disubstituted-1,4-dihydro-5H-tetrazol-5-one derivatives of fentanyl: alfentanil (R 39209), a potent, extremely short-acting narcotic analgesic.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID185210Morphinomimetic activity was determined in rats by tail withdrawal reflex test (TWR), administered by intravenous.1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthetic 1,4-disubstituted-1,4-dihydro-5H-tetrazol-5-one derivatives of fentanyl: alfentanil (R 39209), a potent, extremely short-acting narcotic analgesic.
AID237593Percentage of mass balance in hexadecane membranes model2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Exploring the role of different drug transport routes in permeability screening.
AID409950Inhibition of human brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID174636Duration to produce analgesic activity was measured in rats by tail withdrawal reflex test (TWR), administered by intravenous at peak time 1 min (4 X MED50 dose)1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthetic 1,4-disubstituted-1,4-dihydro-5H-tetrazol-5-one derivatives of fentanyl: alfentanil (R 39209), a potent, extremely short-acting narcotic analgesic.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID174634Duration to produce analgesic activity was measured in rats by tail withdrawal reflex test (TWR), administered by intravenous at peak time 1 min (2 X MED50 dose)1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthetic 1,4-disubstituted-1,4-dihydro-5H-tetrazol-5-one derivatives of fentanyl: alfentanil (R 39209), a potent, extremely short-acting narcotic analgesic.
AID174638Duration to produce analgesic activity was measured in rats by tail withdrawal reflex test (TWR), intravenous administration.1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthetic 1,4-disubstituted-1,4-dihydro-5H-tetrazol-5-one derivatives of fentanyl: alfentanil (R 39209), a potent, extremely short-acting narcotic analgesic.
AID540214Clearance in rat after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID169411Lower limit dose for morphinomimetic activity was determined in rats by tail withdrawal reflex test (TWR),at time 1/32 hour after administration intravenously1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthetic 1,4-disubstituted-1,4-dihydro-5H-tetrazol-5-one derivatives of fentanyl: alfentanil (R 39209), a potent, extremely short-acting narcotic analgesic.
AID178188Effective dose for morphinomimetic activity was determined in rats by tail withdrawal reflex test (TWR),at time 2 hr after administration intravenously1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthetic 1,4-disubstituted-1,4-dihydro-5H-tetrazol-5-one derivatives of fentanyl: alfentanil (R 39209), a potent, extremely short-acting narcotic analgesic.
AID520313Inhibition of CYP3A activity in orally dosed human2008Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5
Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir.
AID496832Antimicrobial activity against Trypanosoma brucei rhodesiense2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID129038Duration of analgesic activity less than 6 min (S) in a standard mouse hot plate assay1989Journal of medicinal chemistry, May, Volume: 32, Issue:5
Synthesis and pharmacological evaluation of 4,4-disubstituted piperidines.
AID496817Antimicrobial activity against Trypanosoma cruzi2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496825Antimicrobial activity against Leishmania mexicana2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID171771Upper limit dose for morphinomimetic activity was determined in rats by tail withdrawal reflex test (TWR),at time 1/8 hr hour after administration intravenously1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthetic 1,4-disubstituted-1,4-dihydro-5H-tetrazol-5-one derivatives of fentanyl: alfentanil (R 39209), a potent, extremely short-acting narcotic analgesic.
AID540216Clearance in dog after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID679130TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 5 uM) in Caco-2 cells2002Anesthesiology, Apr, Volume: 96, Issue:4
Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein.
AID8002Observed volume of distribution2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID169409Lower limit dose for morphinomimetic activity was determined in rats by tail withdrawal reflex test (TWR),at time 1/16 hr hour after administration intravenously1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthetic 1,4-disubstituted-1,4-dihydro-5H-tetrazol-5-one derivatives of fentanyl: alfentanil (R 39209), a potent, extremely short-acting narcotic analgesic.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1576132Displacement of [3H]pentazocine from LAL/HA/BR guinea pig brain sigma1 receptor incubated for 90 mins by liquid scintillation counting method2019MedChemComm, Jul-01, Volume: 10, Issue:7
Affinity of fentanyl and its derivatives for the σ
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID496818Antimicrobial activity against Trypanosoma brucei brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID680128TP_TRANSPORTER: transepithelial transport (basal to apical) in MDR1-expressing LLC-PK1 cells2002Anesthesiology, Apr, Volume: 96, Issue:4
Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein.
AID196363Recovery of motor co-ordination after intravenous injection of ED100 and regaining of righting immediately.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
New 1-(heterocyclylalkyl)-4-(propionanilido)-4-piperidinyl methyl ester and methylene methyl ether analgesics.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID174637Duration to produce analgesic activity was measured in rats by tail withdrawal reflex test (TWR), administered by intravenous at peak time 1 min (8X MED50 dose)1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthetic 1,4-disubstituted-1,4-dihydro-5H-tetrazol-5-one derivatives of fentanyl: alfentanil (R 39209), a potent, extremely short-acting narcotic analgesic.
AID177759Analgesic activity determined by the rat tail flick assay by injection at the lateral tail vein1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
New 1-(heterocyclylalkyl)-4-(propionanilido)-4-piperidinyl methyl ester and methylene methyl ether analgesics.
AID496823Antimicrobial activity against Trichomonas vaginalis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID169453Change in mean arterial pressure of male Sprague-Dawley rats;,as compared to control, using rat tail1989Journal of medicinal chemistry, Dec, Volume: 32, Issue:12
4-Phenyl- and 4-heteroaryl-4-anilidopiperidines. A novel class of analgesic and anesthetic agents.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID169459Change in mean arterial pressure of male Sprague-Dawley rats;,as compared to control, using rat tail flick after the administration of a dose of 16.01989Journal of medicinal chemistry, Dec, Volume: 32, Issue:12
4-Phenyl- and 4-heteroaryl-4-anilidopiperidines. A novel class of analgesic and anesthetic agents.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID174621Duration of analgesic effect calculated using in vivo rat tail withdrawal assay.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Design, synthesis, and pharmacological evaluation of ultrashort- to long-acting opioid analgetics.
AID236912Permeability Coefficient in 2/4/A1 cell model2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Exploring the role of different drug transport routes in permeability screening.
AID409952Inhibition of human brain MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID177757Analgesic activity at 1 min following injection at 1 mg/kg into the lateral tail vein of the rat (55 degree Celsius hot plate assay)1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
New 1-(heterocyclylalkyl)-4-(propionanilido)-4-piperidinyl methyl ester and methylene methyl ether analgesics.
AID177758Analgesic activity determined by the rat hotplate assay by injection at the lateral tail vein1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
New 1-(heterocyclylalkyl)-4-(propionanilido)-4-piperidinyl methyl ester and methylene methyl ether analgesics.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID496829Antimicrobial activity against Leishmania infantum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID496826Antimicrobial activity against Entamoeba histolytica2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID236914Permeability Coefficient in hexadecane membranes model2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Exploring the role of different drug transport routes in permeability screening.
AID129194Time from loss of righting (LOR) to that of righting occurance in anesthetic mouse1989Journal of medicinal chemistry, May, Volume: 32, Issue:5
Synthesis and pharmacological evaluation of 4,4-disubstituted piperidines.
AID540220Clearance in human after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID28399Cellular permeability (Pc) (Caco-2 cell monolayer)2001Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12
Experimental and computational screening models for the prediction of intestinal drug absorption.
AID171768Upper limit dose for morphinomimetic activity was determined in rats by tail withdrawal reflex test (TWR),at time 1/2 hour after administration intravenously1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthetic 1,4-disubstituted-1,4-dihydro-5H-tetrazol-5-one derivatives of fentanyl: alfentanil (R 39209), a potent, extremely short-acting narcotic analgesic.
AID169455Change in mean arterial pressure of male Sprague-Dawley rats;,as compared to control, using rat tail flick after the administration of a dose of 0.41989Journal of medicinal chemistry, Dec, Volume: 32, Issue:12
4-Phenyl- and 4-heteroaryl-4-anilidopiperidines. A novel class of analgesic and anesthetic agents.
AID540218Clearance in monkey after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID1576134Displacement of [3H]DAMGO from rat brain mu opioid receptor incubated for 60 mins by microbeta scintillation counting method2019MedChemComm, Jul-01, Volume: 10, Issue:7
Affinity of fentanyl and its derivatives for the σ
AID169462Change in mean arterial pressure of male Sprague-Dawley rats;,as compared to control, using rat tail flick after the administration of a dose of 8.01989Journal of medicinal chemistry, Dec, Volume: 32, Issue:12
4-Phenyl- and 4-heteroaryl-4-anilidopiperidines. A novel class of analgesic and anesthetic agents.
AID169456Change in mean arterial pressure of male Sprague-Dawley rats;,as compared to control, using rat tail flick after the administration of a dose of 0.51989Journal of medicinal chemistry, Dec, Volume: 32, Issue:12
4-Phenyl- and 4-heteroaryl-4-anilidopiperidines. A novel class of analgesic and anesthetic agents.
AID236915Apparent permeability value in Caco-2 cell culture model2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Exploring the role of different drug transport routes in permeability screening.
AID171769Upper limit dose for morphinomimetic activity was determined in rats by tail withdrawal reflex test (TWR),at time 1/32 hour after administration intravenously1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthetic 1,4-disubstituted-1,4-dihydro-5H-tetrazol-5-one derivatives of fentanyl: alfentanil (R 39209), a potent, extremely short-acting narcotic analgesic.
AID496820Antimicrobial activity against Trypanosoma brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID169525Lower limit dose for morphinomimetic activity was determined in rats by tail withdrawal reflex test (TWR),at time 2 hour after administration intravenously1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthetic 1,4-disubstituted-1,4-dihydro-5H-tetrazol-5-one derivatives of fentanyl: alfentanil (R 39209), a potent, extremely short-acting narcotic analgesic.
AID1576133Displacement of [3H]pentazocine from LAL/HA/BR guinea pig brain sigma1 receptor at 10 uM incubated for 90 mins by liquid scintillation counting method relative to control2019MedChemComm, Jul-01, Volume: 10, Issue:7
Affinity of fentanyl and its derivatives for the σ
AID496821Antimicrobial activity against Leishmania2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID169327Change in heart rate of male Sprague-Dawley rats, as compared to the control, using rat hot plate1989Journal of medicinal chemistry, Dec, Volume: 32, Issue:12
4-Phenyl- and 4-heteroaryl-4-anilidopiperidines. A novel class of analgesic and anesthetic agents.
AID196020Rotarod index for recovery of motor coordination in rats1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
New 1-(heterocyclylalkyl)-4-(propionanilido)-4-piperidinyl methyl ester and methylene methyl ether analgesics.
AID28392Apparent permeability coefficient (Papp) (Caco-2 cell monolayer)2001Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12
Experimental and computational screening models for the prediction of intestinal drug absorption.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID169412Lower limit dose for morphinomimetic activity was determined in rats by tail withdrawal reflex test (TWR),at time 1/4 hour after administration intravenously1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthetic 1,4-disubstituted-1,4-dihydro-5H-tetrazol-5-one derivatives of fentanyl: alfentanil (R 39209), a potent, extremely short-acting narcotic analgesic.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID171770Upper limit dose for morphinomimetic activity was determined in rats by tail withdrawal reflex test (TWR),at time 1/4 hour after administration intravenously1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthetic 1,4-disubstituted-1,4-dihydro-5H-tetrazol-5-one derivatives of fentanyl: alfentanil (R 39209), a potent, extremely short-acting narcotic analgesic.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID178182Effective dose for morphinomimetic activity was determined in rats by tail withdrawal reflex test (TWR),at time 1/16 hr after administration intravenously1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthetic 1,4-disubstituted-1,4-dihydro-5H-tetrazol-5-one derivatives of fentanyl: alfentanil (R 39209), a potent, extremely short-acting narcotic analgesic.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID171773Upper limit dose for morphinomimetic activity was determined in rats by tail withdrawal reflex test (TWR),at time 2 hr after administration intravenously1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthetic 1,4-disubstituted-1,4-dihydro-5H-tetrazol-5-one derivatives of fentanyl: alfentanil (R 39209), a potent, extremely short-acting narcotic analgesic.
AID496827Antimicrobial activity against Leishmania amazonensis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID26789Partition coefficient (logP)1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthetic 1,4-disubstituted-1,4-dihydro-5H-tetrazol-5-one derivatives of fentanyl: alfentanil (R 39209), a potent, extremely short-acting narcotic analgesic.
AID540215Volume of distribution at steady state in rat after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID171772Upper limit dose for morphinomimetic activity was determined in rats by tail withdrawal reflex test (TWR),at time 1 hr after administration intravenously1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthetic 1,4-disubstituted-1,4-dihydro-5H-tetrazol-5-one derivatives of fentanyl: alfentanil (R 39209), a potent, extremely short-acting narcotic analgesic.
AID496830Antimicrobial activity against Leishmania major2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID169328Change in heart rate of male Sprague-Dawley rats, as compared to the control, using rat tail flick1989Journal of medicinal chemistry, Dec, Volume: 32, Issue:12
4-Phenyl- and 4-heteroaryl-4-anilidopiperidines. A novel class of analgesic and anesthetic agents.
AID540221Volume of distribution at steady state in human after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID178184Effective dose for morphinomimetic activity was determined in rats by tail withdrawal reflex test (TWR),at time 1/32 hour after administration intravenously1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthetic 1,4-disubstituted-1,4-dihydro-5H-tetrazol-5-one derivatives of fentanyl: alfentanil (R 39209), a potent, extremely short-acting narcotic analgesic.
AID7783Unbound fraction (plasma)2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID496828Antimicrobial activity against Leishmania donovani2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID178186Effective dose for morphinomimetic activity was determined in rats by tail withdrawal reflex test (TWR),at time 1/8 hr after administration intravenously1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthetic 1,4-disubstituted-1,4-dihydro-5H-tetrazol-5-one derivatives of fentanyl: alfentanil (R 39209), a potent, extremely short-acting narcotic analgesic.
AID177922Analgesic effect calculated using in vivo rat tail withdrawal assay.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Design, synthesis, and pharmacological evaluation of ultrashort- to long-acting opioid analgetics.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID236268Fraction absorbed in human intestine after oral administration compound was measured2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
Exploring the role of different drug transport routes in permeability screening.
AID147961In vitro binding activity against opioid receptor kappa using [3H]EKC) as radioligand1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
New 1-(heterocyclylalkyl)-4-(propionanilido)-4-piperidinyl methyl ester and methylene methyl ether analgesics.
AID496824Antimicrobial activity against Toxoplasma gondii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID23710Apparent coefficient between heptane and water at pH 7.41986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthetic 1,4-disubstituted-1,4-dihydro-5H-tetrazol-5-one derivatives of fentanyl: alfentanil (R 39209), a potent, extremely short-acting narcotic analgesic.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID178185Effective dose for morphinomimetic activity was determined in rats by tail withdrawal reflex test (TWR),at time 1/4 hour after administration intravenously1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthetic 1,4-disubstituted-1,4-dihydro-5H-tetrazol-5-one derivatives of fentanyl: alfentanil (R 39209), a potent, extremely short-acting narcotic analgesic.
AID174635Duration to produce analgesic activity was measured in rats by tail withdrawal reflex test (TWR), administered by intravenous at peak time 1 min (32 X MED50 dose)1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthetic 1,4-disubstituted-1,4-dihydro-5H-tetrazol-5-one derivatives of fentanyl: alfentanil (R 39209), a potent, extremely short-acting narcotic analgesic.
AID178398Effective dose for its analgesic activity in male Sprague-Dawley rats using rat hot plate assay1989Journal of medicinal chemistry, Dec, Volume: 32, Issue:12
4-Phenyl- and 4-heteroaryl-4-anilidopiperidines. A novel class of analgesic and anesthetic agents.
AID497005Antimicrobial activity against Pneumocystis carinii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID151590Ability to displace [3H]naloxone from the Opioid receptor mu 1 isolated from the rat brain membranes.1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Synthesis and pharmacological evaluation of a series of new 3-methyl-1,4-disubstituted-piperidine analgesics.
AID169330Change in heart rate of male Sprague-Dawley rats, as compared to the control, using rat tail flick after the administration of a dose of 0.51989Journal of medicinal chemistry, Dec, Volume: 32, Issue:12
4-Phenyl- and 4-heteroaryl-4-anilidopiperidines. A novel class of analgesic and anesthetic agents.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID231333Ratio of [(apical to basal)/(basal to apical)] (Caco-2 cell monolayer)2001Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12
Experimental and computational screening models for the prediction of intestinal drug absorption.
AID73902Inhibition of electrically evoked contraction in guinea pig ileum determined in vitro1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Design, synthesis, and pharmacological evaluation of ultrashort- to long-acting opioid analgetics.
AID169448Change in heart rate of male Sprague-Dawley rats, as compared to the control, using rat tail flick after the administration of a dose of 8.01989Journal of medicinal chemistry, Dec, Volume: 32, Issue:12
4-Phenyl- and 4-heteroaryl-4-anilidopiperidines. A novel class of analgesic and anesthetic agents.
AID26362Ionization constant (pKa)2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID189327Analgesic activity by observing the recovery of motor coordination in rats1989Journal of medicinal chemistry, Dec, Volume: 32, Issue:12
4-Phenyl- and 4-heteroaryl-4-anilidopiperidines. A novel class of analgesic and anesthetic agents.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID131732Analgesic activity using mouse hot plate technique at 55 degree Centigrade1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Synthesis and pharmacological evaluation of a series of new 3-methyl-1,4-disubstituted-piperidine analgesics.
AID149187In vitro binding activity against opioid receptor delta using [3H]DPDPE) as radioligand at 10000 uM concentration1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
New 1-(heterocyclylalkyl)-4-(propionanilido)-4-piperidinyl methyl ester and methylene methyl ether analgesics.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID592681Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
QSAR-based permeability model for drug-like compounds.
AID134893Dose required to produce loss of righting (LOR) in anesthetic mouse1989Journal of medicinal chemistry, May, Volume: 32, Issue:5
Synthesis and pharmacological evaluation of 4,4-disubstituted piperidines.
AID169329Change in heart rate of male Sprague-Dawley rats, as compared to the control, using rat tail flick after the administration of a dose of 0.41989Journal of medicinal chemistry, Dec, Volume: 32, Issue:12
4-Phenyl- and 4-heteroaryl-4-anilidopiperidines. A novel class of analgesic and anesthetic agents.
AID540217Volume of distribution at steady state in dog after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID169408Lower limit dose for morphinomimetic activity was determined in rats by tail withdrawal reflex test (TWR),at time 1 hour after administration intravenously1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthetic 1,4-disubstituted-1,4-dihydro-5H-tetrazol-5-one derivatives of fentanyl: alfentanil (R 39209), a potent, extremely short-acting narcotic analgesic.
AID178183Effective dose for morphinomimetic activity was determined in rats by tail withdrawal reflex test (TWR),at time 1/2 hour after administration intravenously1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthetic 1,4-disubstituted-1,4-dihydro-5H-tetrazol-5-one derivatives of fentanyl: alfentanil (R 39209), a potent, extremely short-acting narcotic analgesic.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID603953In-vivo plasma to lung partition coefficients of the compound, logP(lung) in rat2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,658)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990397 (23.94)18.7374
1990's744 (44.87)18.2507
2000's322 (19.42)29.6817
2010's147 (8.87)24.3611
2020's48 (2.90)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 60.29

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index60.29 (24.57)
Research Supply Index7.82 (2.92)
Research Growth Index4.52 (4.65)
Search Engine Demand Index107.18 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (60.29)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials757 (43.73%)5.53%
Reviews60 (3.47%)6.00%
Case Studies89 (5.14%)4.05%
Observational2 (0.12%)0.25%
Other823 (47.54%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (41)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Efficacy of Alfentanyl Versus Sufentanyl in Children for Pain During Treatment by Tracheal Suction in an Intensive Care Unit. [NCT01235637]Phase 340 participants (Actual)Interventional2010-06-30Completed
Effects of Pre-medication With Alfentanil on Hemodynamics During and Immediately Following Electroconvulsive Therapy (ECT) [NCT03359395]Phase 4100 participants (Actual)Interventional2018-06-04Completed
Alfentanil vs Remifentanil in Patient-controlled Sedation During ERCP.A Randomized Double-blind Study [NCT01350037]Phase 481 participants (Actual)Interventional2009-06-30Completed
The Effect of Alfentanil on the Lower Esophageal Sphincter During Anesthesia Induction - a Study in Volunteers [NCT01199458]Phase 417 participants (Actual)Interventional2010-09-30Completed
Patient-Controlled Sedation in Port Implantation (PACSPI-2) -a Randomized Controlled Trial [NCT05688384]Phase 4340 participants (Anticipated)Interventional2023-01-19Recruiting
Optimal Dose of Alfentanil for Removal of Supreme Laryngeal Mask Airway During Emergence From Desflurane Anaesthesia [NCT01371968]30 participants (Actual)Interventional2011-02-28Completed
Propofol Versus Midazolam Plus Alfentanil for Sedation During Flexible Bronchoscopy: Respiratory Depression Comparison Inspected by Cutaneous Carbon Dioxide Tension Level [NCT01289327]115 participants (Actual)Interventional2010-04-30Completed
The Effects of Remifentanil and Remifentanil-Alfentanil Administration on Emergence Agitation After Brief Ophthalmic Surgery in Children [NCT02486926]102 participants (Actual)Interventional2012-11-30Completed
Standardised Drug Provocation Testing in Perioperative Hypersensitivity [NCT06065137]Phase 450 participants (Anticipated)Interventional2023-10-31Not yet recruiting
Evaluation of Fentalogs and Their Metabolites in Hair of Patients in a Monitored Clinical Context by Means of Hair Analysis [NCT05740657]225 participants (Anticipated)Observational [Patient Registry]2022-12-06Recruiting
Can we Get Conscious Sedation in Optimal Safety Conditions in an Emergency Department, by Combining Dexmedetomidine With Alfentanil? [NCT02358057]Phase 440 participants (Actual)Interventional2015-02-28Completed
Success of Sedation During Bronchoscopy: Comparison of the Effects of Dexmedetomidine, Alfentanil and Local Anesthesia [NCT01805726]Phase 3162 participants (Actual)Interventional2013-02-28Completed
An Open-label Pilot Comparison Between Alfentanil and Diamorphine for Palliative Care Patients Who Require Subcutaneous Opioids [NCT01049672]18 participants (Actual)Interventional2010-09-30Completed
Nurse-Administered Propofol Sedation by PCA Pump Versus Diazemuls / Pethidine in Outpatient Colonoscopy: A Randomized Controlled Study [NCT00566683]194 participants (Actual)Interventional2005-07-31Completed
Safety and Efficacy of Sedation for Flexible Fiberoptic Bronchoscopy: Comparison of Propofol/Alfentanil With Propofol/Ketamine [NCT02000206]80 participants (Anticipated)Interventional2014-02-28Not yet recruiting
Propofol Versus Alfentanil Versus Nitrous Oxide for Moderate Procedural Sedation in the Emergency Department [NCT00997126]Phase 4126 participants (Actual)Interventional2009-10-31Completed
Prevention of Emergence Agitation in Children After Sevoflurane Anesthesia With Ketamine-midazolam Combination: A Prospective Randomized Clinical Trial [NCT02022488]Phase 478 participants (Actual)Interventional2012-02-29Completed
Efficacy and Safety of Ciprofol for General Anaesthesia in Patients Undergoing Transcatheter Aortic Valve Replacement [NCT05881291]124 participants (Anticipated)Interventional2023-06-29Recruiting
Alfentanil and the Elimination of Sympathetic Responses to Tracheal Intubation During Rapid Sequence Induction of Anesthesia: A Probability-based Approach [NCT01518608]Phase 484 participants (Actual)Interventional2009-09-30Completed
Effect of a Bolus of 10 µg/kg of Alfentanil on the Pupillary Pain Index [NCT02646592]14 participants (Actual)Interventional2016-04-30Completed
Triple Drug Response Surface Modeling for Patients Receiving Airway Managements [NCT03813875]100 participants (Actual)Observational2019-06-12Completed
Neuronale Mechanismen Der Sensorischen Reizverarbeitung in Der Narkose [NCT00434382]768 participants Interventional2002-10-31Active, not recruiting
International Review Board of Gachon University Gil Hospital [NCT01436799]40 participants (Actual)Interventional2011-03-31Completed
Heritability of Opioid Effects: A Twin Study [NCT00672438]242 participants (Actual)Interventional2008-05-31Completed
A Pilot Study of Prolonged, Intermittent Exposure to Alfentanil on Opioid-Induced Hyperalgesia in Healthy Volunteers [NCT00991809]22 participants (Actual)Interventional2009-02-28Completed
[NCT00440960]Phase 40 participants InterventionalCompleted
Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care [NCT01431326]3,520 participants (Actual)Observational2011-11-30Completed
Physiologic Stress During Procedural Sedation With and Without Alfentanil [NCT00997113]Phase 420 participants (Actual)Interventional2009-10-31Completed
Investigation of Analgesic and Anti-inflammatory Effects of Beta-adrenergic Antagonist Propranolol [NCT01094574]10 participants (Actual)Interventional2010-01-31Completed
The Optimal Regimen of Alfentanil in Propofol Sedative Fibro-bronchoscopy:a Prospective Randomized, Double-blind, Placebo-controlled Trial [NCT01470170]Phase 4173 participants (Actual)Interventional2010-10-31Completed
[NCT01550354]114 participants (Actual)Interventional2012-02-29Completed
The Effect of mu Opioid Receptor Polymorphism on the Response to Alfentanil During Lithotripsy [NCT00226564]100 participants Interventional1997-08-31Completed
Comparison of Bupivacaine-Fentanyl and Bupivacaine-Alfentanil Used Intrathecally in Laparoscopic Appendectomy Surgery [NCT04196946]50 participants (Actual)Interventional2013-09-02Completed
Novel Noninvasive Assessment of Cytochrome P4450 Activity: Simultaneous Testing Pilot [NCT01008059]6 participants (Actual)Interventional2009-10-31Completed
The Effects of Fentanyl and Alfentanil as an Adjunct to Propofol on Cognitive Functions for Sedation in Colonoscopy [NCT02267681]Phase 4150 participants (Actual)Interventional2014-10-31Completed
The Application and Validation of Triple Drug Response Surface Models on Density Spectral Array in Clinical Anesthesia [NCT05525351]60 participants (Anticipated)Observational2022-10-31Not yet recruiting
Comparison of Postoperative Pain Application of Alfentanil or Remifentanil in TIVA Undergoing Functional Endoscopic Sinus Surgery [NCT05344911]Phase 4130 participants (Actual)Interventional2022-04-29Completed
Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis [NCT02625181]27,034 participants (Actual)Interventional2016-07-31Completed
Patient-controlled Sedation in Port Implantation (PACSPI-1)-a Feasibility Trial [NCT04631393]40 participants (Actual)Observational2021-04-14Completed
Pain Evaluation During Follicle Aspiration: Comparison of Two Sedation Protocols [NCT00742807]Phase 40 participants (Actual)Interventional2008-08-31Withdrawn(stopped due to No investigator to follow-up)
A Randomized, Controlled Trial to Compare the Efficacy and Safety Profile of a Remimazolam-alfentanil Combination With a Propofol-alfentanil Combination for ERCP [NCT04658173]1,000 participants (Anticipated)Interventional2020-12-22Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00672438 (14) [back to overview]Cold Pain Threshold
NCT00672438 (14) [back to overview]Maximum Nausea
NCT00672438 (14) [back to overview]Maximum Drug Liking
NCT00672438 (14) [back to overview]Maximum Drug Disliking
NCT00672438 (14) [back to overview]Heat Pain Threshold
NCT00672438 (14) [back to overview]Transcutaneous Partial Pressure of Carbon Dioxide
NCT00672438 (14) [back to overview]Cold Pain Tolerance
NCT00672438 (14) [back to overview]Average Drug Liking
NCT00672438 (14) [back to overview]Average Nausea
NCT00672438 (14) [back to overview]Average Pruritis
NCT00672438 (14) [back to overview]Maximum Pruritis
NCT00672438 (14) [back to overview]Respiratory Rate
NCT00672438 (14) [back to overview]Sedation
NCT00672438 (14) [back to overview]Sedation by Patient Report
NCT00991809 (2) [back to overview]Pain Tolerance
NCT00991809 (2) [back to overview]Pain Threshold
NCT00997113 (3) [back to overview]Respiratory Depression
NCT00997113 (3) [back to overview]Patient Reported Pain and Recall of the Painful Procedure for Which They Were Sedated Measure by Patient Query After They Had Regained Their Baseline Level of Consciousness After the Procedure
NCT00997113 (3) [back to overview]Change in Serum Catecholamines
NCT00997126 (5) [back to overview]Time to Return of Baseline Mental Status From Start of Procedure in Minutes
NCT00997126 (5) [back to overview]Depth of Sedation Measured Using the OAAS Scale
NCT00997126 (5) [back to overview]Number of Participants With Sub-clinical Respiratory Depression and Clinical Events Associated With Respiratory Depression During the Sedation Procedure
NCT00997126 (5) [back to overview]Patient Reported Pain
NCT00997126 (5) [back to overview]Patient Reported Recall of the Procedure
NCT01008059 (1) [back to overview]Area Under the Curve of Alfentanil Concentration vs. Time Extrapolated to Infinity
NCT01094574 (13) [back to overview]Change From Baseline in Mechanical Pain Threshold During Infusion in Non-Inflamed Skin
NCT01094574 (13) [back to overview]Change From Baseline in Heat Pain Threshold During Infusion in Inflamed Skin
NCT01094574 (13) [back to overview]Change From Baseline in Heat Pain Threshold During Infusion in Non-Inflamed Skin
NCT01094574 (13) [back to overview]Change From Baseline in Mechanical Pain Threshold During Infusion in Inflamed Skin
NCT01094574 (13) [back to overview]Change in Arbitrary Perfusion Units From Baseline During Drug Infusion
NCT01094574 (13) [back to overview]GMCSF (ng/mL) Change From Baseline During Infusion
NCT01094574 (13) [back to overview]IL-10 (ng/mL) Change From Baseline During Infusion
NCT01094574 (13) [back to overview]IL-12 (ng/mL) Change From Baseline During Infusion
NCT01094574 (13) [back to overview]IL-1β (ng/mL) Change From Baseline During Infusion
NCT01094574 (13) [back to overview]IL-2 (ng/mL) Change From Baseline During Infusion
NCT01094574 (13) [back to overview]IL-6 (ng/mL) Change From Baseline During Infusion
NCT01094574 (13) [back to overview]IL-8 (ng/mL) Change From Baseline During Infusion
NCT01094574 (13) [back to overview]TNFα (ng/mL) Change From Baseline During Infusion
NCT01436799 (1) [back to overview]Regional Cerebral Oxygen Satuation (rSO2)
NCT01470170 (5) [back to overview]Effect Site Concentration When Conscious Level Reaches OAAS-3
NCT01470170 (5) [back to overview]Induction Time, Time Period That Will be Required for Conscious Level to Reach OAAS-3
NCT01470170 (5) [back to overview]Hypotension
NCT01470170 (5) [back to overview]Hypoxemia
NCT01470170 (5) [back to overview]Propofol Dose Needed to Reach Conscious Level OAAS-3
NCT02625181 (4) [back to overview]Adherence to PONV Guidelines
NCT02625181 (4) [back to overview]PONV Incidence: Number of Participants With Postoperative Nausea and Vomiting
NCT02625181 (4) [back to overview]The Number of Prophylactic Interventions for PONV
NCT02625181 (4) [back to overview]Time to Discharge From the Postanesthesia Care Unit (PACU)
NCT03359395 (10) [back to overview]Minimum Heart Rate
NCT03359395 (10) [back to overview]Maximum Heart Rate
NCT03359395 (10) [back to overview]Heart Rate
NCT03359395 (10) [back to overview]Heart Rate
NCT03359395 (10) [back to overview]Systolic Blood Pressure Change
NCT03359395 (10) [back to overview]Total Time Subject Spent In-Room
NCT03359395 (10) [back to overview]Diastolic Blood Pressure Change
NCT03359395 (10) [back to overview]Time to Return of Spontaneous Ventilation
NCT03359395 (10) [back to overview]Severity of Headache in the Post Anesthesia Care Unit
NCT03359395 (10) [back to overview]Satisfaction With the Anesthetic Post-procedure

Cold Pain Threshold

"Time in seconds~Sensitivity to cold-pressor pain was tested by asking subjects to immerse their hand up to the wrist in ice water (1-2 C) continuously re-circulated within a 12-L container with the palm of the hand in full contact with the bottom of the container.They were asked to indicate the onset of pain - reported as pain threshold." (NCT00672438)
Timeframe: Participants underwent the pain testing measures at training prior to study procedures, at baseline and during each of the infusions.

InterventionSeconds (Median)
Alfentanil Infusion15
Saline Infusion8

[back to top]

Maximum Nausea

"At the end of an infusion stage participants were asked to rate the maximum severity of nausea on a 100-mm visual analog scale (VAS) anchored by the words not at all and as much as possible. This means that the scale is 100mm long where one extreme end of the scale represents 0, and 0 represents no nausea experienced. The other extreme end of the scale represents 100, and 100 represents as much nausea as possible. Participants are asked to indicate what point on that continuum best represents their maximum experience of nausea." (NCT00672438)
Timeframe: At the end of each infusion stage. 2 times total.

Interventionnumerical score (Median)
Alfentanil Infusion8
Saline Infusion0

[back to top]

Maximum Drug Liking

"At the end of an infusion stage participants were asked, What was the maximum that you liked the drug at any moment (VAS)? (100-mm VAS, 0 _ not at all, 100 _ as much as possible)? The VAS scale is 100mm long where one extreme end of the scale represents 0, and 0 indicates the participant did not like the drug experience. The other extreme end of the scale represents 100, and 100 indicates that the participant liked the drug experience as much as possible. Participants are asked to indicate what point on that continuum best represents the their experience." (NCT00672438)
Timeframe: At the end of each infusion stage. 2 times total.

Interventionnumerical score (Median)
Alfentanil Infusion75
Saline Infusion0

[back to top]

Maximum Drug Disliking

"At the end of an infusion stage participants were asked, What was the maximum that you disliked the drug at any moment (VAS)? (100-mm VAS, 0 _ not at all, 100 _ as much as possible)? The VAS scale is 100mm long where one extreme end of the scale represents 0, and 0 indicates the participant did not like the drug experience. The other extreme end of the scale represents 100, and 100 indicates that the participant liked the drug experience as much as possible. Participants are asked to indicate what point on that continuum best represents the most they disliked the drug experience." (NCT00672438)
Timeframe: At the end of each infusion stage. 2 times total.

Interventionnumerical score (Median)
Alfentanil Infusion23
Saline Infusion0

[back to top]

Heat Pain Threshold

"Degrees Centigrade~Heat pain was induced with a thermal sensory analyzer (TSA-II, Medoc Advanced Medical Systems, Durham, North Carolina). A thermode was placed in contact with skin at the volar forearm. Starting at a comfortable temperature, the thermode temperature was increased at a measured rate. Study participants pushed a button of a hand-held device at the onset of pain at which point the thermode immediately reduced the temperature." (NCT00672438)
Timeframe: Participants underwent the pain testing measures at training prior to study procedures, at baseline and during each of the infusions.

Interventiondegrees centigrade (Median)
Alfentanil Infusion49.6
Saline Infusion48.6

[back to top]

Transcutaneous Partial Pressure of Carbon Dioxide

Partial pressure of transcutaneous carbon dioxide (CO2) was measured with aid of a pO2/pCO2-electrode (Perimed Inc., North Royalton, OH) mounted to the anterior chest wall. (NCT00672438)
Timeframe: Measured continuously throughout the study session ~ 5 hours

InterventionmmHg (Median)
Alfentanil Infusion47.7
Saline Infusion40.3

[back to top]

Cold Pain Tolerance

"Time in seconds~Sensitivity to cold-pressor pain was tested by asking subjects to immerse their hand up to the wrist in ice water (1-2 C) continuously re-circulated within a 12-L container with the palm of the hand in full contact with the bottom of the container.They were asked to remove their hand from the water bath when it was no longer tolerable - reported as pain tolerance." (NCT00672438)
Timeframe: Participants underwent the pain testing measures at training prior to study procedures, at baseline and during each of the infusions.

InterventionSeconds (Median)
Alfentanil Infusion32
Saline Infusion17

[back to top]

Average Drug Liking

"At the end of an infusion stage participants were asked, How much did you like the drug on average (100-mm VAS, 0 _ not at all, 100 _ as much as possible)? The VAS scale is 100mm long where one extreme end of the scale represents 0, and 0 indicates the participant did not like the drug experience. The other extreme end of the scale represents 100, and 100 indicates that the participant liked the drug experience as much as possible. Participants are asked to indicate what point on that continuum best represents the their experience." (NCT00672438)
Timeframe: At the end of each infusion stage. 2 times total.

Interventionnumerical score (Median)
Alfentanil Infusion50
Saline Infusion0

[back to top]

Average Nausea

"At the end of an infusion stage participants were asked to rate the average severity of nausea on a 100-mm visual analog scale (VAS) anchored by the words not at all and as much as possible. This means that the scale is 100mm long where one extreme end of the scale represents 0, and 0 represents no nausea experienced. The other extreme end of the scale represents 100, and 100 represents as much nausea as possible. Participants are asked to indicate what point on that continuum best represents their average experience." (NCT00672438)
Timeframe: At the end of each infusion stage. 2 times total.

Interventionnumerical score (Median)
Alfentanil Infusion1
Saline Infusion0

[back to top]

Average Pruritis

"At the end of an infusion stage participants were asked to rate the average severity of pruritis on a 100-mm visual analog scale (VAS) anchored by the words not at all and as much as possible. This means that the scale is 100mm long where one extreme end of the scale represents 0, and 0 represents no pruritis experienced. The other extreme end of the scale represents 100, and 100 represents as much pruritis as possible. Participants are asked to indicate what point on that continuum best represents their average experience of pruritis." (NCT00672438)
Timeframe: At the end of each infusion stage. 2 times total.

Interventionnumerical score (Median)
Alfentanil Infusion20
Saline Infusion0

[back to top]

Maximum Pruritis

"At the end of an infusion stage participants were asked to rate the maximum severity of pruritis on a 100-mm visual analog scale (VAS) anchored by the words not at all and as much as possible. This means that the scale is 100mm long where one extreme end of the scale represents 0, and 0 represents no pruritis experienced. The other extreme end of the scale represents 100, and 100 represents as much pruritis as possible. Participants are asked to indicate what point on that continuum best represents their maximun experience of pruritis." (NCT00672438)
Timeframe: At the end of each infusion stage. 2 times total.

Interventionnumerical score (Median)
Alfentanil Infusion35
Saline Infusion0

[back to top]

Respiratory Rate

Breaths per minute counted by direct observation and additionally recorded / external electronic monitoring. (NCT00672438)
Timeframe: Measured throughout the study session ~ 5 hours

InterventionBreaths per minute (Median)
Alfentanil Infusion11
Saline Infusion14

[back to top]

Sedation

Sedative opioid effects were assessed with the trail-making test (TMT) (Angst et al., 2004; Oswald and Roth, 1987). The TMT is a paper-and pencil test consisting of 4 different matrices listing numbers 1-90 in a 9 × 10 format. Subsequent numbers are located in neighboring rows or columns. Matrices were allocated randomly. Subjects had to connect numbers 1-90 as quickly as possible and the time to completion was recorded. (NCT00672438)
Timeframe: The trail making test was performed at training prior to study procedures, at baseline, and during each of the infusions.

InterventionTime in seconds (Median)
Alfentanil Infusion70
Saline Infusion63

[back to top]

Sedation by Patient Report

"Sedation was assessed by measuring cognitive speed and by asking participants to indicate on a 100-mm visual analog scale (VAS) how sedated they felt. This means that the scale is 100mm long where one extreme end of the scale represents 0, and 0 represents no sedation was experienced. The other extreme end of the scale represents 100, and 100 represents as much sedation as possible. Participants are asked to indicate what point on that continuum best represents their experience of sedation." (NCT00672438)
Timeframe: At the end of each infusion stage. 2 times total.

Interventionnumerical score (Median)
Alfentanil Infusion75
Saline Infusion0

[back to top]

Pain Tolerance

The participant places their hand in a water bath kept at 4 degrees Celsius (cold pressor test). They then continue to hold the hand in the water bath until they can no longer tolerate the pain (pain tolerance) or until the end of the testing (truncated at 300 seconds for safety purposes). Reported as the mean (time to hand removal in seconds) at the 30 minute time point. (NCT00991809)
Timeframe: 8 sessions over 4-6 weeks

Interventionseconds (Mean)
Alfentanil105.3
Diphenhydramine19.2

[back to top]

Pain Threshold

The amount of time (in seconds) before the participant first verbally reports feeling pain after placing hand in 4 degree Celsius circulating water bath at the 30 minute time point. Truncated at 300 seconds for safety purposes. (NCT00991809)
Timeframe: 8 sessions over 4-6 weeks

Interventionseconds (Mean)
Alfentanil20.7
Diphenhydramine8.6

[back to top]

Respiratory Depression

categorized as a change in end tidal CO2 from baseline >10mmhg, a loss of end tidal CO2 waveform for more than 6 seconds, or an oxygen saturation less than 93%. (NCT00997113)
Timeframe: From one minute prior to the start of the sedation procedure until the patient has returned to baseline mental status

Interventionparticipants (Number)
Propofol4
Propofol/Alfentanil5

[back to top]

Patient Reported Pain and Recall of the Painful Procedure for Which They Were Sedated Measure by Patient Query After They Had Regained Their Baseline Level of Consciousness After the Procedure

Pain and recall were measured seperately by direct patient query. The patient was asked if they experienced any pain during the procedure. The patient was then asked if they could recall any part of the fracture reduction. Patients who had either pain with the procedure of recall of the procedure were counted as having pain or recall with the procedure. (NCT00997113)
Timeframe: single time point measured after sedation procedure completed

Interventionparticipants (Number)
Propofol2
Propofol/Alfentanil5

[back to top]

Change in Serum Catecholamines

change in serum catecholamine levels, values indicate a decrease over the procedure. These patients underwent fracture reduction procedures which are typically associated with an increase in catecholamines. (NCT00997113)
Timeframe: one minute prior to the start of the procedure and immediately at the end of sedation procedure (median time of procedure 12 minutes range 6-26 minutes

Interventionmcg/ml (Median)
Propofol87
Propofol/Alfentanil106

[back to top]

Time to Return of Baseline Mental Status From Start of Procedure in Minutes

(NCT00997126)
Timeframe: Single time point after completion of sedation procedure, measured from start of procedure until the patient returns to baseline mental status up to 24 hours

Interventionminutes (Median)
Propofol13
Alfentanil13

[back to top]

Depth of Sedation Measured Using the OAAS Scale

Observers Assesment of Alertness Scale, 5 responds normally to voice, 4 lethargic response to voice, 3 responds only to loud voice or light touch, 2 responds only to mild prodding or shaking, 1 responds only to painful stimuli, 0 no response to painful stimuli (NCT00997126)
Timeframe: Single measurement during sedation procedure

Interventionunits on a scale (Median)
Propofol2
Alfentanil3

[back to top]

Number of Participants With Sub-clinical Respiratory Depression and Clinical Events Associated With Respiratory Depression During the Sedation Procedure

(NCT00997126)
Timeframe: From one minute prior to start of procedure until the patient has returned to baseline mental status after the conclusion of the sedation procedure (~3-60 minutes depending on procedure duration)

Interventionparticipants (Number)
Propofol11
Alfentanil12

[back to top]

Patient Reported Pain

(NCT00997126)
Timeframe: Single measurement immediately after patient returns to baseline mental status after sedation procedure

Interventionparticipants (Number)
Propofol7
Alfentanil25

[back to top]

Patient Reported Recall of the Procedure

(NCT00997126)
Timeframe: Single measurement immediately after patient returns to baseline mental status after sedation procedure

Interventionparticipants (Number)
Propofol13
Alfentanil39

[back to top]

Area Under the Curve of Alfentanil Concentration vs. Time Extrapolated to Infinity

AUC(0-inf) (NCT01008059)
Timeframe: 9 hours

Intervention(hr*ng/ml/mg) (Mean)
Simultaneous ControlSimultaneous RifampinSimultaneous GrapefruitSimultaneous ketoconazoleSequential ControlSequential RifampinSequential GrapefruitSequential Ketoconazole
Alfentanil5857557359545973

[back to top]

Change From Baseline in Mechanical Pain Threshold During Infusion in Non-Inflamed Skin

A metal rod of 0.24 mm diameter mounted onto 10 different weights (1.0, 2.0, 4.1, 8.2,16.3, 20, 32.7,49.0, 65.3, and 81.3g) will be placed perpendicularly onto the skin. Starting with the lightest probe, consecutively heavier probes will be used until a subject reports pain. Subsequently, the same or the next lighter probe will be used if pain is reported for the preceding stimulus, or the same or the next heavier probe will be used if no pain is reported for the preceding stimulus.The procedure will be repeated until seven perceptional changes (painful/non-painful) are registered. Measurements for analgesia were taken at the sites of non-injured skin. Change form baseline was calculated by subtracting baseline values from the average values obtained 1 and 2 hours after starting the drug infusion. (NCT01094574)
Timeframe: Participants underwent the pain testing measures at baseline and at 1 and 2 hours after startingthe drug infusion.

Interventionweight in grams (Mean)
Alfentanil10.16
Propranolol-11.22
Placebo-9.53

[back to top]

Change From Baseline in Heat Pain Threshold During Infusion in Inflamed Skin

Degrees Centigrade Heat pain was induced with a thermal sensory analyzer (TSA-II, Medoc Advanced Medical Systems, Durham, North Carolina). A thermode was placed in contact with skin on the upper thigh. Starting at a comfortable temperature, the thermode temperature was increased at a measured rate. Study participants pushed a button of a hand-held device at the onset of pain at which point the thermode immediately reduced the temperature. Measurements for anti-hyperalgesia were taken at the sites of tissue injury. Change form baseline was calculated by subtracting baseline values from the average values obtained 1 and 2 hours after starting the drug infusion. (NCT01094574)
Timeframe: Participants underwent the pain testing measures at baseline and at 1 and 2 hours after startingthe drug infusion.

Interventiondegrees centigrade (Mean)
Alfentanil3.77
Propranolol0.09
Placebo-0.28

[back to top]

Change From Baseline in Heat Pain Threshold During Infusion in Non-Inflamed Skin

Degrees Centigrade Heat pain was induced with a thermal sensory analyzer (TSA-II, Medoc Advanced Medical Systems, Durham, North Carolina). A thermode was placed in contact with skin on the upper thigh. Starting at a comfortable temperature, the thermode temperature was increased at a measured rate. Study participants pushed a button of a hand-held device at the onset of pain at which point the thermode immediately reduced the temperature. Measurements for analgesia were taken at the sites of non-injured skin. Change form baseline was calculated by subtracting baseline values from the average values obtained 1 and 2 hours after starting the drug infusion. (NCT01094574)
Timeframe: Participants underwent the pain testing measures at baseline and at 1 and 2 hours after startingthe drug infusion.

Interventiondegree centigrade (Mean)
Alfentanil1.01
Propranolol0.14
Placebo0.01

[back to top]

Change From Baseline in Mechanical Pain Threshold During Infusion in Inflamed Skin

A metal rod of 0.24 mm diameter mounted onto 10 different weights (1.0, 2.0, 4.1, 8.2,16.3, 20, 32.7,49.0, 65.3, and 81.3g) will be placed perpendicularly onto the skin. Starting with the lightest probe, consecutively heavier probes will be used until a subject reports pain. Subsequently, the same or the next lighter probe will be used if pain is reported for the preceding stimulus, or the same or the next heavier probe will be used if no pain is reported for the preceding stimulus.The procedure will be repeated until seven perceptional changes (painful/non-painful) are registered. Measurements for anti-hyperalgesia were taken at the sites of tissue injury. Change form baseline was calculated by subtracting baseline values from the average values obtained 1 and 2 hours after starting the drug infusion. (NCT01094574)
Timeframe: Participants underwent the pain testing measures at baseline and at 1 and 2 hours after startingthe drug infusion.

Interventionweight in grams (Mean)
Alfentanil29.18
Propranolol-9.07
Placebo-11.00

[back to top]

Change in Arbitrary Perfusion Units From Baseline During Drug Infusion

Laser Doppler images were recorded at baseline and at 2 and 3 hours after starting the drug infusion to provide measurements of peripheral blood flow as an objective measure of inflammation. Blood flow was quantified by arbitrary perfusion units. Baseline measurements were subtracted from the average measurements obtained 2 and 3 hours after starting the drug infusion. (NCT01094574)
Timeframe: Laser doppler images were recorded at baseline and at 2 and 3 hours after starting the drug infusion

Interventionrelative flux (Mean)
Alfentanil-234
Propranolol-217
Placebo-178

[back to top]

GMCSF (ng/mL) Change From Baseline During Infusion

GMCSF (ng/mL) was measured in interstitial fluid after collecting samples as follows: Microdialysis catheters (very small, custom-made, sterile, semi-permeable, micro-dialysis catheters) were placed after the 1st laser Doppler measurement. Two catheters were placed at an experimentally inflamed skin site on the left leg. A continuous infusion of sterile 1% albumin solution was started using a programmable pump set at a rate of 2.5µl/min. Samples were collected hourly throughout the remainder of the study day. Samples for analysis were collected before, and 2 and 3 hours after starting the drug infusion. Difference form baseline was calculated by subtracting the baseline concentration form the average concentration determined in samples collected during drug infusion. (NCT01094574)
Timeframe: Tissue samples were collected at baseline, and 2 and 3 hours after starting the drug infusion.

Interventionng/ml (Mean)
Alfentanil7.85
Propranolol10.75
Placebo6.48

[back to top]

IL-10 (ng/mL) Change From Baseline During Infusion

IL-10 (ng/mL) was measured in interstitial fluid after collecting samples as follows: Microdialysis catheters (very small, custom-made, sterile, semi-permeable, micro-dialysis catheters) were placed after the 1st laser Doppler measurement. Two catheters were placed at an experimentally inflamed skin site on the left leg. A continuous infusion of sterile 1% albumin solution was started using a programmable pump set at a rate of 2.5µl/min. Samples were collected hourly throughout the remainder of the study day. Samples for analysis were collected before, and 2 and 3 hours after starting the drug infusion. Difference form baseline was calculated by subtracting the baseline concentration form the average concentration determined in samples collected during drug infusion. (NCT01094574)
Timeframe: Tissue samples were collected at baseline, and 2 and 3 hours after starting the drug infusion.

Interventionng/ml (Mean)
Alfentanil0.35
Propranolol0.84
Placebo-0.01

[back to top]

IL-12 (ng/mL) Change From Baseline During Infusion

IL-12 (ng/mL) was measured in interstitial fluid after collecting samples as follows: Microdialysis catheters (very small, custom-made, sterile, semi-permeable, micro-dialysis catheters) were placed after the 1st laser Doppler measurement. Two catheters were placed at an experimentally inflamed skin site on the left leg. A continuous infusion of sterile 1% albumin solution was started using a programmable pump set at a rate of 2.5µl/min. Samples were collected hourly throughout the remainder of the study day. Samples for analysis were collected before, and 2 and 3 hours after starting the drug infusion. Difference form baseline was calculated by subtracting the baseline concentration form the average concentration determined in samples collected during drug infusion. (NCT01094574)
Timeframe: Tissue samples were collected at baseline, and 2 and 3 hours after starting the drug infusion.

Interventionng/ml (Mean)
Alfentanil2.12
Propranolol3.41
Placebo3.38

[back to top]

IL-1β (ng/mL) Change From Baseline During Infusion

IL-1β (ng/mL) was measured in interstitial fluid after collecting samples as follows: Microdialysis catheters (very small, custom-made, sterile, semi-permeable, micro-dialysis catheters) were placed after the 1st laser Doppler measurement. Two catheters were placed at an experimentally inflamed skin site on the left leg. A continuous infusion of sterile 1% albumin solution was started using a programmable pump set at a rate of 2.5µl/min. Samples were collected hourly throughout the remainder of the study day. Samples for analysis were collected before, and 2 and 3 hours after starting the drug infusion. Difference form baseline was calculated by subtracting the baseline concentration form the average concentration determined in samples collected during drug infusion. (NCT01094574)
Timeframe: Tissue samples were collected at baseline, and 2 and 3 hours after starting the drug infusion.

Interventionng/ml (Mean)
Alfentanil5.39
Propranolol6.99
Placebo7.53

[back to top]

IL-2 (ng/mL) Change From Baseline During Infusion

IL-2 (ng/mL) was measured in interstitial fluid after collecting samples as follows: Microdialysis catheters (very small, custom-made, sterile, semi-permeable, micro-dialysis catheters) were placed after the 1st laser Doppler measurement. Two catheters were placed at an experimentally inflamed skin site on the left leg. A continuous infusion of sterile 1% albumin solution was started using a programmable pump set at a rate of 2.5µl/min. Samples were collected hourly throughout the remainder of the study day. Samples for analysis were collected before, and 2 and 3 hours after starting the drug infusion. Difference form baseline was calculated by subtracting the baseline concentration form the average concentration determined in samples collected during drug infusion. (NCT01094574)
Timeframe: Tissue samples were collected at baseline, and 2 and 3 hours after starting the drug infusion.

Interventionng/ml (Mean)
Alfentanil2.38
Propranolol3.08
Placebo1.65

[back to top]

IL-6 (ng/mL) Change From Baseline During Infusion

IL-6 (ng/mL) was measured in interstitial fluid after collecting samples as follows: Microdialysis catheters (very small, custom-made, sterile, semi-permeable, micro-dialysis catheters) were placed after the 1st laser Doppler measurement. Two catheters were placed at an experimentally inflamed skin site on the left leg. A continuous infusion of sterile 1% albumin solution was started using a programmable pump set at a rate of 2.5µl/min. Samples were collected hourly throughout the remainder of the study day. Samples for analysis were collected before, and 2 and 3 hours after starting the drug infusion. Difference form baseline was calculated by subtracting the baseline concentration form the average concentration determined in samples collected during drug infusion. (NCT01094574)
Timeframe: Tissue samples were collected at baseline, and 2 and 3 hours after starting the drug infusion.

Interventionng/ml (Mean)
Alfentanil344.2
Propranolol214.0
Placebo153.6

[back to top]

IL-8 (ng/mL) Change From Baseline During Infusion

IL-8 (ng/mL) was measured in interstitial fluid after collecting samples as follows: Microdialysis catheters (very small, custom-made, sterile, semi-permeable, micro-dialysis catheters) were placed after the 1st laser Doppler measurement. Two catheters were placed at an experimentally inflamed skin site on the left leg. A continuous infusion of sterile 1% albumin solution was started using a programmable pump set at a rate of 2.5µl/min. Samples were collected hourly throughout the remainder of the study day. Samples for analysis were collected before, and 2 and 3 hours after starting the drug infusion. Difference form baseline was calculated by subtracting the baseline concentration form the average concentration determined in samples collected during drug infusion. (NCT01094574)
Timeframe: Tissue samples were collected at baseline, and 2 and 3 hours after starting the drug infusion.

Interventionng/ml (Mean)
Alfentanil486.3
Propranolol621.5
Placebo398.7

[back to top]

TNFα (ng/mL) Change From Baseline During Infusion

TNFα (ng/mL) was measured in interstitial fluid after collecting samples as follows: Microdialysis catheters (very small, custom-made, sterile, semi-permeable, micro-dialysis catheters) were placed after the 1st laser Doppler measurement. Two catheters were placed at an experimentally inflamed skin site on the left leg. A continuous infusion of sterile 1% albumin solution was started using a programmable pump set at a rate of 2.5µl/min. Samples were collected hourly throughout the remainder of the study day. Samples for analysis were collected before, and 2 and 3 hours after starting the drug infusion. Difference form baseline was calculated by subtracting the baseline concentration form the average concentration determined in samples collected during drug infusion. (NCT01094574)
Timeframe: Tissue samples were collected at baseline, and 2 and 3 hours after starting the drug infusion.

Interventionng/ml (Mean)
Alfentanil4.92
Propranolol5.78
Placebo2.93

[back to top]

Regional Cerebral Oxygen Satuation (rSO2)

definitive values of regional cerebral oxygen saturation(rSO2,%) values are described as mean (SD) (NCT01436799)
Timeframe: 1, 3, 5, 7, and 9 min after the beach chair position

,
Interventionpercentage of rSO2 (%) (Mean)
1min after beach chair position3min after beach chair position5min after beach chair position7min after beach chair position9min after beach chair position
Desflurane77.47675.275.174
Propofol72.5707068.567.8

[back to top]

Effect Site Concentration When Conscious Level Reaches OAAS-3

After the administration of alfentanil and propofol, the effect site concentration was recorded at the time when the consciousness level reaches observer assessment of alertness and sedation scale 3 (OAAS-3). The effect site concentration is the concentration of drug propofol in brain calculated by TCI using Schnider model. (NCT01470170)
Timeframe: All participants wil be follow for the duration of bronchoscope room stay, an expect average of 2 hours

Interventionug/ml (Mean)
Group12.3
Group 22.2
Group 32.5
Group 42.2
Group 5 /Control2.6

[back to top]

Induction Time, Time Period That Will be Required for Conscious Level to Reach OAAS-3

After the administration of Alfentanil and Propofol, the time period required to reach conscious level OAAS-3 will be recorded. (NCT01470170)
Timeframe: All participants wil be follow for the duration of bronchoscope room stay, an expect average of 2 hours

Interventionsecond (Mean)
Group1279
Group 2263
Group 3374
Group 4247
Group 5 /Control402

[back to top]

Hypotension

Check the frequency of hypotension episode during induction, procedure and recovery time (NCT01470170)
Timeframe: All participants wil be follow for the duration of bronchoscope room stay, an expect average of 2 hours

,,,,
Interventionparticipants (Number)
Induction timeProcedure timeRecovery time
Group 2174
Group 30114
Group 4052
Group 5 /Control064
Group1274

[back to top]

Hypoxemia

Check the frequency of hypoxemia episode during induction, procedure, and recovery time (NCT01470170)
Timeframe: All participants wil be follow for the duration of bronchoscope room stay, an expect average of 2 hours

,,,,
Interventionparticipants (Number)
Induction timeProcedure timeRecovery time
Group 29102
Group 31165
Group 46154
Group 5 /Control1185
Group11135

[back to top]

Propofol Dose Needed to Reach Conscious Level OAAS-3

After the administration of Alfentanil and Propofol, the Propofol dose needed to reach conscious level of observer assessment of alertness and sedation scale 3 (OAAS-3) will be recorded. (NCT01470170)
Timeframe: All participants wil be follow for the duration of bronchoscope room stay, an expect average of 2 hours

Interventionmg (Mean)
Group167.8
Group 256.4
Group 375.3
Group 454.8
Group 5 /Control76.3

[back to top]

Adherence to PONV Guidelines

PONV guideline adherence: percentage of patients who received the exact number of prophylactic interventions for PONV that were recommended by the decision support. (NCT02625181)
Timeframe: A specific time frame on the day of surgery: the start of admission at the holding room to the end of the anesthetic case

InterventionParticipants (Count of Participants)
Baseline Measurement666
CDS Email Recommendations5260
CDS Email + Real TIme Recommenations5863

[back to top]

PONV Incidence: Number of Participants With Postoperative Nausea and Vomiting

The occurrence of PONV, as defined by the administration of antiemetics in the PACU between admission to PACU and discharge from PACU. (NCT02625181)
Timeframe: PACU recovery period

InterventionParticipants (Count of Participants)
Baseline Measurement139
CDS Email Recommendations1323
CDS Email + Real TIme Recommenations1343

[back to top]

The Number of Prophylactic Interventions for PONV

the absolute number of prophylactic interventions applied between the admission of the patient in the holding room until admission to the PACU. (NCT02625181)
Timeframe: A specific time frame on the day of surgery: from the start of admission at the holding room to the end of the anesthetic case

Interventionprophylactic antiemetics administered (Mean)
Baseline Measurement2.196
CDS Email Recommendations2.176
CDS Email + Real TIme Recommenations2.129

[back to top]

Time to Discharge From the Postanesthesia Care Unit (PACU)

This is the number of minutes from admission to the PACU until discharge, assessed up to 2 days (NCT02625181)
Timeframe: A specific time frame on the day of surgery: from the start of admission to the PACU to discharge from the PACU

Interventionminutes (Mean)
Baseline Measurement266
CDS Email Recommendations264
CDS Email + Real TIme Recommenations266

[back to top]

Minimum Heart Rate

comparison of heart rate change alfentanil vs placebo (NCT03359395)
Timeframe: Baseline and up to 90 minutes

InterventionBeats per Minute (Mean)
Alfentanil12.74
Placebo7.08

[back to top]

Maximum Heart Rate

comparison of heart rate change alfentanil vs placebo (NCT03359395)
Timeframe: Baseline and up to 90 minutes

InterventionBeats per Minute (Mean)
Alfentanil44.33
Placebo49.66

[back to top]

Heart Rate

comparison of heart rate change alfentanil vs placebo (NCT03359395)
Timeframe: Baseline and up to 30 seconds

InterventionBeats per Minute (Mean)
Alfentanil37.48
Placebo36.93

[back to top]

Heart Rate

comparison of heart rate change alfentanil vs placebo (NCT03359395)
Timeframe: Baseline and up to 15 seconds

InterventionBeats per Minute (Mean)
Alfentanil26.00
Placebo28.197674418604

[back to top]

Systolic Blood Pressure Change

comparison of Systolic blood pressure changes alfentanil vs placebo (NCT03359395)
Timeframe: Baseline and up to 90 minutes

InterventionmmHg (Mean)
Alfentanil22.011
Placebo38.908

[back to top]

Total Time Subject Spent In-Room

comparison of amounts time spent in-room between the 2 groups (NCT03359395)
Timeframe: up to 90 minutes

InterventionMinutes (Mean)
Alfentanil17.51
Placebo16.43

[back to top]

Diastolic Blood Pressure Change

comparison of diastolic blood pressure change alfentanil vs placebo (NCT03359395)
Timeframe: Baseline and up to 90 minutes

InterventionmmHg (Mean)
Alfentanil15.26
Placebo23.34

[back to top]

Time to Return of Spontaneous Ventilation

time to return to breathing without assistance (NCT03359395)
Timeframe: up to 90 minutes

InterventionMinutes (Mean)
Alfentanil8.17
Placebo7.25

[back to top]

Severity of Headache in the Post Anesthesia Care Unit

comparison between alfentanil vs placebo - Subject questionnaire with scale: 0 -10 - with 10 being the worst (NCT03359395)
Timeframe: up to 90 minutes

Interventionscore on a scale (Mean)
Alfentanil2
Placebo2.467

[back to top]

Satisfaction With the Anesthetic Post-procedure

comparison between alfentanil vs placebo - Subject questionnaire with scale: 0-10 - with 10 being the worst (NCT03359395)
Timeframe: up to 90 minutes

Interventionscore on a scale (Mean)
Alfentanil8
Placebo8.033

[back to top]